Document:

<PAGE>
                                                                     EXHIBIT 4.3

                                 PURPLE RAY, INC.
                                 2000 STOCK PLAN

1.      Purposes of the Plan. The purposes of this Stock Plan are to attract and
retain the best available personnel for positions of substantial responsibility,
to provide additional incentive to Employees and Consultants of the Company and
its Subsidiaries and to promote the success of the Company's business. Options
granted under the Plan may be incentive stock options (as defined under Section
422 of the Code) or non-statutory stock options, as determined by the
Administrator at the time of grant of an option and subject to the applicable
provisions of Section 422 of the Code, as amended, and the regulations
promulgated thereunder. Stock purchase rights may also be granted under the
Plan.

2.      Definitions.  As used herein, the following definitions shall apply:

        (a) "ADMINISTRATOR" means the Board or any of its Committees appointed
pursuant to Section 4 of the Plan.

        (b) "APPLICABLE LAWS" means the requirements relating to the
administration of stock option plans under U.S. state corporate laws, U.S.
federal and state securities laws, the Code, any stock exchange or quotation
system on which the Common Stock is listed or quoted and the applicable laws of
any other country or jurisdiction where Options or Stock Purchase Rights are
granted under the Plan.

        (c) "BOARD" means the Board of Directors of the Company.

        (d) "CODE" means the Internal Revenue Code of 1986, as amended.

        (e) "COMMITTEE" means the Committee, if any, appointed by the Board of
Directors in accordance with paragraph (a) of Section 4 of the Plan.

        (f) "COMMON STOCK" means the Common Stock of the Company.

        (g) "COMPANY" means Purple Ray, Inc., a California corporation.

        (h) "CONSULTANT" means any person, including an advisor, who is engaged
by the Company or any Parent or Subsidiary to render advisory or consulting
services and is compensated for such services, and any director of the Company
whether compensated for such services or not; provided that if and in the event
the Company registers any class of any equity security pursuant to the Exchange
Act, the term Consultant shall thereafter not include directors who are not
compensated for their services or are paid only a director's fee by the Company.

        (i) "CONTINUOUS STATUS AS AN EMPLOYEE" means the absence of any
interruption or termination of the employment relationship by the Company or any
Subsidiary. Continuous Status as an Employee shall not be considered interrupted
in the case of: (i) sick leave, military leave or any other leave of absence
approved by the Board, provided that such leave is for a period of not more than
ninety (90) days, unless reemployment upon the expiration of such leave is
guaranteed by contract or statute, or unless provided otherwise pursuant to
Company policy adopted from time to time; or

                                       1
<PAGE>

(ii) in the case of transfers between locations of the Company or
between the Company, its Subsidiaries or its successor.

        (j) "EMPLOYEE" means any person, including officers and directors,
employed by the Company or any Parent or Subsidiary of the Company. The payment
of a director's fee by the Company shall not be sufficient to constitute
"employment" by the Company.

        (k) "EXCHANGE ACT" means the Securities Exchange Act of 1934, as
amended.

        (l) "FAIR MARKET VALUE" means, as of any date, the value of Common Stock
determined as follows:

         (i) If the Common Stock is then quoted on the NASDAQ National Market,
  its closing price on the NASDAQ National Market on the date of determination
  as reported in The Wall Street Journal;

         (ii) If the Common Stock is publicly traded and is then listed on a
  national securities exchange, its closing price on the date of determination
  on the principal national securities exchange on which the Common Stock is
  listed or admitted to trading as reported in The Wall Street Journal;

         (iii) If the Common Stock is publicly traded but is not quoted on the
  NASDAQ National Market nor listed or admitted to trading on a national
  securities exchange, the average of the closing bid and asked prices on the
  date of determination as reported in The Wall Street Journal; or

         (iv) If none of the foregoing is applicable, the Fair Market Value
  thereof shall be determined in good faith by the Board.

        (m) "INCENTIVE STOCK OPTION" means an Option intended to qualify as an
incentive stock option within the meaning of Section 422 of the Code.

        (n) "NONSTATUTORY STOCK OPTION" means an Option not intended to qualify
as an Incentive Stock Option.

        (o) "OPTION" means a stock option granted pursuant to the Plan.

        (p) "OPTIONED STOCK" means the Common Stock subject to an Option.

        (q) "OPTIONEE" means an Employee or Consultant who receives an Option.

        (r) "PARENT" means a "parent corporation", whether now or hereafter
existing, as defined in Section 424(e) of the Code.

        (s) "PLAN" means this Stock Plan, as amended from time to time.

        (t) "PURCHASER" means an Employee or Consultant who exercises a Stock
Purchase Right.

                                       2
<PAGE>

        (u) "SERVICE" means the provision of services to the Company or any
Parent or Subsidiary by an individual in the capacity of an Employee, a
non-employee member of the board of directors or a Consultant.

        (v) "SHARE" means a share of the Common Stock, as adjusted in accordance
with Section 12 of the Plan.

        (w) "STOCK PURCHASE RIGHT" means the right to purchase Restricted Stock
granted pursuant to Section 11 of the Plan.

        (x) "SUBSIDIARY" means a "subsidiary corporation", whether now or
hereafter existing, as defined in Section 424(f) of the Code.

        (y) "TOUCH UP OPTION" means an Option designated as a "Touch Up Option"
by the Administrator and granted to an existing Optionee from time to time after
the initial grant of Options to such Optionee.

3.      Stock Subject to the Plan. Subject to the provisions of Section 12 of
the Plan, the maximum aggregate number of shares which may be optioned and sold
under the Plan is 8,800,000 Shares of Common Stock. The shares may be
authorized, but unissued, or reacquired Common Stock. If an Option or Stock
Purchase Right should expire or become unexercisable for any reason without
having been exercised in full, the unpurchased Shares which were subject thereto
shall, unless the Plan shall have been terminated, become available for future
grant under the Plan.

4.      Administration of the Plan.

        (a) Procedure. The Plan shall be administered by the Board or by a
Committee designated by the Board to administer the Plan. Once appointed, such
Committee shall continue to serve in its designated capacity until otherwise
directed by the Board. From time to time the Board may increase the size of the
Committee and appoint additional members thereof, remove members (with or
without cause) and appoint new members in substitution therefor, fill vacancies,
however caused, and remove all members of the Committee and thereafter directly
administer the Plan, all in accordance with the legal requirements relating to
the administration of incentive stock option plans, if any, of California
corporate and securities laws and of the Code (the "Applicable Laws").

        (b) Powers of the Administrator. Subject to the provisions of the Plan
and in the case of a Committee, the specific duties delegated by the Board to
such Committee, the Administrator shall have the authority, in its discretion:

            (i) to determine the Fair Market Value of the Common Stock, in
accordance with Section 2 of the Plan;

            (ii) to select the Consultants and Employees to whom Options and
Stock Purchase Rights may from time to time be granted hereunder;

            (iii) to determine whether and to what extent Options and Stock
Purchase Rights or any combination thereof, are granted hereunder;

                                       3
<PAGE>

            (iv) to determine the number of shares of Common Stock to be covered
by each such award granted hereunder;

            (v) to approve forms of agreement for use under the Plan;

            (vi) to determine the terms and conditions, not inconsistent with
the terms of the Plan, of any award granted hereunder (including, but not
limited to the share price and any restriction or limitation, based in each case
on such factors as the Administrator shall determine, in its sole discretion);

            (vii) to determine the terms and restrictions applicable to Stock
Purchase Rights and the Restricted Stock purchased by exercising such Stock
Purchase Rights;

            (viii) to prescribe, amend and rescind rules and regulations
relating to the Plan, including rules and regulations relating to sub-plans
established for the purpose of qualifying for preferred tax treatment under
foreign tax laws;

            (ix) to allow Optionees to satisfy withholding tax obligations by
electing to have the Company withhold from the Shares to be issued upon exercise
of an Option or Stock Purchase Right that number of Shares having a Fair Market
Value equal to the amount required to be withheld. The Fair Market Value of the
Shares to be withheld shall be determined on the date that the amount of tax to
be withheld is to be determined. All elections by Optionees to have Shares
withheld for this purpose shall be made in such form and under such conditions
as the Administrator may deem necessary or advisable;

            (x) to provide, in accordance with any policies of the Company, for
suspension or modification of vesting upon an Optionee's status as an Employee
or Consultant, including changes (without limitation) in status from Employee to
Consultant or visa versa and changes in status from full time to part-time
Employee;

            (xi) to make any other such determinations with respect to awards
under the Plan as it shall deem appropriate, including (without limitation)
determinations with respect to vesting, exercisability and price adjustments;
and

            (xii) to grant additional Touch-Up Options to Optionees, at such
times and in such amounts as the Administrator shall determine, in its sole
discretion.

        (c) Effect of Administrator's Decision. All decisions, determinations
and interpretations of the Administrator shall be final and binding on all
Optionees and Purchasers and any other holders of any Options or Stock Purchase
Rights.

5.      Eligibility for Options.

        (a) Nonstatutory Stock Options may be granted to Employees and
Consultants. Incentive Stock Options may be granted only to Employees. An
Employee or Consultant who has been granted an Option may, if he is otherwise
eligible, be granted an additional Option or Options.

                                       4
<PAGE>

        (b) Each Option shall be designated in the written option agreement as
either an Incentive Stock Option or a Nonstatutory Stock Option. However,
notwithstanding such designations, to the extent that the aggregate Fair Market
Value of the Shares with respect to which Options designated as Incentive Stock
Options are exercisable for the first time by any Optionee during any calendar
year (under all plans of the Company or any Parent or Subsidiary) exceeds
$100,000, such excess Options shall be treated as Nonstatutory Stock Options.

        (c) For purposes of Section 5(b), Incentive Stock Options shall be taken
into account in the order in which they were granted, and the Fair Market Value
of the Shares shall be determined as of the time the Option with respect to such
Shares is granted.

        (d) The Plan shall not confer upon any Optionee any right with respect
to continuation of employment or consulting relationship with the Company, nor
shall it interfere in any way with his right or the Company's right to terminate
his employment or consulting relationship at any time, with or without cause.

        (e) From time to time and at least annually, the Administrator may
determine that an initial grant of Options to an Optionee is insufficient based
on the level of the Optionee's service to the Company, and that Touch Up Options
should be granted to such Optionees. The Administrator shall have the sole
discretion to grant Touch Up Options on such terms and conditions as shall be
determined by the Administrator, and nothing contained herein shall require the
Administrator to grant any such Options.

6.      Term of Plan. The Plan shall become effective upon the earlier to occur
of its adoption by the Board of Directors or its approval by the shareholders of
the Company as described in Section 18 of the Plan. It shall continue in effect
for a term of ten (10) years unless sooner terminated under Section 14 of the
Plan.

7.      Term of Option. The term of each Option shall be the term stated in the
Option Agreement; provided, however, that no Option, shall have a term which
ends more than ten (10) years from the date of its grant. In the case of an
Incentive Stock Option granted to an Optionee who, at the time the Option is
granted, owns stock representing more than ten percent (10%) of the voting power
of all classes of stock of the Company or any Parent or Subsidiary, the term of
such Incentive Stock Option shall end no more than five (5) years from the date
of its grant .

8.      Option Exercise Price and Consideration.

        (a) The per share exercise price for the Shares to be issued pursuant to
exercise of an Option shall be such price as is determined by the Board, but
shall be subject to the following:

            (i) In the case of an Incentive Stock Option

                (A) granted to an Employee who, at the time of the grant of such
Incentive Stock Option, owns stock representing more than ten percent (10%) of
the voting power of all classes of stock of the Company or any Parent or
Subsidiary, the per Share exercise price shall be no less than 110% of the Fair
Market Value per Share on the date of grant.

                                       5
<PAGE>

                 (B) granted to any Employee, the per Share exercise price shall
be no less than 100% of the Fair Market Value per Share on the date of grant.

            (ii) In the case of a Nonstatutory Stock Option

                 (A) granted to a person who, at the time of the grant of such
Option, owns stock representing more than ten percent (10%) of the voting power
of all classes of stock of the Company or any Parent or Subsidiary, the per
Share exercise price shall be no less than 110% of the Fair Market Value per
Share on the date of the grant.

                 (B) granted to any person, the per Share exercise price shall
be no less than 85% of the Fair Market Value per Share on the date of grant.

        (b) The consideration to be paid for the Shares to be issued upon
exercise of an Option, including the method of payment, shall be determined by
the Administrator (and, in the case of an Incentive Stock Option, shall be
determined at the time of grant) and may consist entirely of (i) cash, (ii)
check, (iii) other Shares which (x) in the case of Shares acquired upon exercise
of an Option either have been owned by the Optionee for more than six months on
the date of surrender or were not acquired, directly or indirectly, from the
Company, and (y) have a Fair Market Value on the date of surrender equal to the
aggregate exercise price of the Shares as to which said Option shall be
exercised, (iv) authorization for the Company to retain from the total number of
Shares as to which the Option is exercised that number of Shares having a Fair
Market Value on the date of exercise equal to the exercise price for the total
number of Shares as to which the Option is exercised, (v) delivery of a properly
executed exercise notice together with irrevocable instructions to a broker to
promptly deliver to the Company the amount of sale or loan proceeds required to
pay the exercise price, (vi) by delivering an irrevocable subscription agreement
for the Shares which irrevocably obligates the option holder to take and pay for
the Shares not more than twelve months after the date of delivery of the
subscription agreement, (vii) any combination of the foregoing methods of
payment, (viii) or such other consideration and method of payment for the
issuance of Shares to the extent permitted under Applicable Laws. In making its
determination as to the type of consideration to accept, the Board shall
consider if acceptance of such consideration may be reasonably expected to
benefit the Company.

9.      Exercise of Option.

        (a) Procedure for Exercise; Rights as a Shareholder. Any Option granted
hereunder shall be exercisable at such times and under such conditions as
determined by the Board, including performance criteria with respect to the
Company and/or the Optionee, and as shall be permissible under the terms of the
Plan.

            (i) An Option may not be exercised for a fraction of a Share. An
Option shall be deemed to be exercised when written notice of such exercise has
been given to the Company in accordance with the terms of the Option by the
person entitled to exercise the Option and the Administrator has determined that
payment for the Shares with respect to which the Option is exercised has been
received by the Company. Full payment may, as authorized by the Administrator,
consist of any consideration and method of payment allowable under Section 8(b)
of the Plan. Exercise

                                       6
<PAGE>

of an Option in any manner shall result in a decrease in the number of Shares
which thereafter may be available, both for purposes of the Plan and for sale
under the Option, by the number of Shares as to which the Option is exercised.

            (ii) Until the issuance (as evidenced by the appropriate entry on
the books of the Company or of a duly authorized transfer agent of the Company)
of the stock certificate evidencing such Shares, no right to vote or receive
dividends or any other rights as a shareholder shall exist with respect to the
Optioned Stock, notwithstanding the exercise of the Option. The Company shall
issue (or cause to be issued) such stock certificate promptly upon exercise of
the Option. No adjustment will be made for a dividend or other right for which
the record date is prior to the date the stock certificate is issued, except as
provided in Section 11 of the Plan.

            (iii) The Plan Administrator shall have the discretion to authorize
the issuance of unvested shares of Common Stock under the Plan. Should the
optionee cease Service while holding such unvested shares, the Company shall
have the right to repurchase, at the exercise price paid per share, all or (at
the discretion of the Company) any of those shares which have not vested. The
terms and conditions upon which such repurchase right shall be exercisable
(including the period and procedure for exercise and the appropriate vesting
schedule for the purchased shares) shall be established by the Plan
Administrator and set forth in the applicable notice of option grant and stock
purchase agreement. In no event, however, may the Plan Administrator impose a
vesting schedule upon any option granted under the Plan or any shares of Common
Stock subject to the option which is more restrictive than twenty percent (20%)
per year vesting, beginning one (1) year after the grant date.

        (b) Termination of Employment. In the event of termination of an
Optionee's consulting relationship or Continuous Status as an Employee with the
Company (as the case may be), such Optionee may, but within no less than thirty
(30) days after the date of such termination (or such other longer period as is
set out by the Administrator in the Option Agreement, but in no event later than
the expiration date of the term of such Option as set forth in the Option
Agreement), exercise the Option to the extent that Optionee was entitled to
exercise it at the date of such termination. To the extent that Optionee was not
entitled to exercise the Option at the date of such termination, or if Optionee
does not exercise such Option to the extent so entitled within the time
specified herein, the Option shall terminate. Notwithstanding anything to the
contrary contained herein, in the event that the Optionee's employment has
terminated for cause (as determined by the Administrator in accordance with the
policies of the Company), the Option shall terminate immediately on the date of
termination of employment.

        (c) Disability of Optionee. Notwithstanding the provisions of Section
9(b) above, in the event of termination of an Optionee's consulting relationship
or Continuous Status as an Employee as a result of his disability (as determined
by the Administrator in accordance with the policies of the Company), Optionee
may, but within no less than six (6) months from the date of such termination
(or such other longer period as is set out by the Administrator in the Option
Agreement, but in no event later than the expiration date of the term of such
Option as set forth in the Option Agreement), exercise the Option to the extent
otherwise entitled to exercise it at the date of such termination. To the extent
that Optionee was not entitled to exercise the Option at the date of
termination, or if Optionee does not exercise such Option to the extent so
entitled within the time specified herein, the Option shall terminate.

                                       7
<PAGE>

        (d) Death of Optionee. In the event of the death of an Optionee, the
Option may be exercised, at any time within twelve (12) months following the
date of death (but in no event later than the expiration date of the term of
such Option as set forth in the Option Agreement), by the Optionee's estate or
by a person who acquired the right to exercise the Option by bequest or
inheritance, but only to the extent the Optionee was entitled to exercise the
Option at the date of death. To the extent that Optionee was not entitled to
exercise the Option at the date of death, or if Optionee does not exercise such
Option to the extent so entitled within the time specified herein, the Option
shall terminate.

10.     Non-Transferability of Options. An Option may not be sold, pledged,
assigned, hypothecated, transferred, or disposed of in any manner other than by
will or by the laws of descent or distribution and may be exercised, during the
lifetime of the Optionee, only by the Optionee.

11.     Stock Purchase Rights.

        (a) Rights to Purchase Restricted Stock. Stock Purchase Rights may be
issued to Employees and Consultants either alone, in addition to, or in tandem
with other awards granted under the Plan and/or cash awards made outside of the
Plan. After the Administrator determines that it will offer Stock Purchase
Rights under the Plan, it shall advise the offeree in writing of the terms,
conditions and restrictions related to the offer, including the number of Shares
that such person shall be entitled to purchase, the price to be paid, and the
time within which such person must accept such offer, which shall in no event
exceed one-hundred twenty (120) days from the date of grant of the Stock
Purchase Right. For these purposes, the price to be paid shall be no less than
85% of Fair Market Value on the date of grant of the Stock Purchase Right or, in
the case of a greater than 10% shareholder, no less than 100% of the Fair Market
Value on the date of grant. The offer shall be accepted by execution of a
Restricted Stock agreement in the form determined by the Administrator. Shares
purchased pursuant to the grant of a Stock Purchase Right shall be referred to
herein as "Restricted Stock."

        (b) Repurchase Option. Unless the Administrator determines otherwise,
the Restricted Stock agreement shall grant the Company a repurchase option
exercisable upon the voluntary or involuntary termination of the Purchaser's
employment with the Company for any reason (including death or Disability). The
purchase price for Shares repurchased pursuant to the Restricted Stock agreement
shall be the original price paid by the Purchaser and may be paid by
cancellation of any indebtedness of the purchaser to the Company. The repurchase
option with respect to the Restricted Stock shall lapse at such rate as the
Committee may determine, but in no event as to less than 20% of the total shares
granted annually.

        (c) Other Provisions. The Restricted Stock agreement shall contain such
other terms, provisions and conditions not inconsistent with the Plan as may be
determined by the Administrator in its sole discretion. In addition, the
provisions of Restricted Stock agreements need not be the same with respect to
each purchaser.

        (d) Rights as a Shareholder. Once the Stock Purchase Right is exercised,
the Purchaser shall have the rights equivalent to those of a shareholder, and
shall be a shareholder when his or her purchase is entered upon the records of
the duly authorized

                                       8
<PAGE>

transfer agent of the Company. No adjustment will be made for a dividend or
other right for which the record date is prior to the date the Stock Purchase
Right is exercised, except as provided in Section 12 of the Plan.

12.     Adjustments Upon Changes in Capitalization or Merger.

        (a) Changes in Capitalization. Subject to any required action by the
shareholders of the Company, the number of shares of Common Stock covered by
each outstanding Option or Stock Purchase Right, and the number of shares of
Common Stock which have been authorized for issuance under the Plan but as to
which no Options or Stock Purchase Rights have yet been granted or which have
been returned to the Plan upon cancellation or expiration of an Option or Stock
Purchase Right, as well as the price per share of Common Stock covered by each
such outstanding Option or Stock Purchase Right, shall be proportionately
adjusted for any increase or decrease in the number of issued shares of Common
Stock resulting from a stock split, reverse stock split, stock dividend,
combination or reclassification of the Common Stock, or any other increase or
decrease in the number of issued shares of Common Stock effected without receipt
of consideration by the Company; provided, however, that conversion of any
convertible securities of the Company shall not be deemed to have been "effected
without receipt of consideration." Such adjustment shall be made by the Board,
whose determination in that respect shall be final, binding and conclusive.
Except as expressly provided herein, no issuance by the Company of shares of
stock of any class, or securities convertible into shares of stock of any class,
shall affect, and no adjustment by reason thereof shall be made with respect to,
the number or price of shares of Common Stock subject to an Option or Stock
Purchase Right.

        (b) Corporate Transactions. In the event of the proposed dissolution or
liquidation of the Company, or of a sale or merger in which the survivor
corporation does not agree to assume the Option or Stock Purchase Right or
substitute an equivalent Option or Stock Purchase Right, the Board shall notify
Optionees and Purchasers at least fifteen (15) days prior to such proposed
action and, in its discretion, permit Optionees to exercise their Options to the
extent already vested or make a determination to accelerate vesting of any
outstanding Options or Stock Purchase Rights. To the extent it has not been
previously exercised, the Option or Stock Purchase Right will terminate
immediately prior to the consummation of such proposed action.

13.     Time of Granting Options. The date of grant of an Option shall, for all
purposes, be the date on which the Administrator makes the determination
granting such Option, or such other date as is determined by the Board. Notice
of the determination shall be given to each Employee or Consultant to whom an
Option is so granted within a reasonable time after the date of such grant.

14.     Amendment and Termination of the Plan.

        (a) Amendment and Termination. The Board may at any time amend, alter,
suspend or discontinue the Plan, but no amendment, alteration, suspension or
discontinuation shall be made which would impair the rights of any Optionee or
Purchaser under any grant theretofore made, without his or her consent. In
addition, to the extent necessary and desirable to comply with Applicable Laws,
the Company shall obtain shareholder approval of any Plan amendment in such a
manner and to such a degree as required.

                                       9
<PAGE>

        (b) Effect of Amendment or Termination. Any such amendment or
termination of the Plan shall not affect Options and Stock Purchase Rights
already granted and such Options and Stock Purchase Rights shall remain in full
force and effect as if this Plan had not been amended or terminated, unless
mutually agreed otherwise between the Optionee or Purchaser and the Board, which
agreement must be in writing and signed by the Optionee or Purchaser and the
Company.

15.     Conditions Upon Issuance of Shares. Shares shall not be issued pursuant
to the exercise of an Option or Stock Purchase Right unless the exercise of such
Option or Stock Purchase Right and the issuance and delivery of such Shares
pursuant thereto shall comply with all relevant provisions of law, including,
without limitation, the Securities Act of 1933, as amended, the Exchange Act,
the rules and regulations promulgated thereunder, and the requirements of any
stock exchange upon which the Shares may then be listed, and shall be further
subject to the approval of counsel for the Company with respect to such
compliance. As a condition to the exercise of an Option or Stock Purchase Right,
the Company may require the person exercising such Option or Stock Purchase
Right to represent and warrant at the time of any such exercise that the Shares
are being purchased only for investment and without any present intention to
sell or distribute such Shares if, in the opinion of counsel for the Company,
such a representation is required by any of the aforementioned relevant
provisions of law.

16.     Reservation of Shares. The Company, during the term of this Plan, will
at all times reserve and keep available such number of Shares as shall be
sufficient to satisfy the requirements of the Plan. The inability of the Company
to obtain authority from any regulatory body having jurisdiction, which
authority is deemed by the Company's counsel to be necessary to the lawful
issuance and sale of any Shares hereunder, shall relieve the Company of any
liability in respect of the failure to issue or sell such Shares as to which
such requisite authority shall not have been obtained.

17.     Agreements. Options and Stock Purchase Rights shall be evidenced by
written agreements in such form as the Board shall approve from time to time.

18.     Shareholder Approval. Continuance of the Plan shall be subject to
approval by the shareholders of the Company within twelve (12) months before or
after the date the Plan is adopted. Such shareholder approval shall be obtained
in the degree and manner required under applicable state and federal law.

19.     Information to Optionees. The Company shall provide to each Optionee,
during the period for which such Optionee has one or more Options outstanding,
annual financial statements of the Company. The Company shall not be required to
provide such information if the issuance of Options under the Plan is limited to
key employees whose duties in connection with the Company assure their access to
equivalent information.

                                       10
<PAGE>

                                PURPLE RAY, INC.

                                 2000 STOCK PLAN

                          NOTICE OF STOCK OPTION GRANT

[Optionee's Name]
[Address]

        You have been granted an Option, consisting of the Terms and Conditions
of Stock Option Agreement ("Terms and Conditions") attached hereto as Exhibit A
and this Notice of Stock Option Grant (together, the "Option Agreement") to
purchase Common Stock of Purple Ray, Inc., (the "Company") as follows:

        Date of Grant                                 [x]
                                                  ---------------------------

        Vesting Commencement Date                     [x]
                                                  ---------------------------

        Option Price Per Share                     $ [x]
                                                  ---------------------------

        Total Number of Shares subject to the         [x]
        Option ("Option Shares")
                                                  ---------------------------

        Total Price of Option Shares               $ [x]
                                                  ---------------------------

        Type of Option                            ___ Incentive Stock Option

                                                  ___ Nonqualified Stock Option

        Term/Expiration Date                      10 years/   [x]
                                                            -----------------

        Exercise Schedule:
        -----------------

        This Option may be exercised before the expiration of the Termination
Period defined below, subject to the Terms and Conditions, in accordance with
the Vesting Schedule set out below. If the Plan Administrator allows an earlier
exercise of the Option, the Option Shares will vest in accordance with the
Vesting Schedule set out below.

        Vesting Schedule

               Date of Vesting                         Number of Vested Shares
               ---------------                         -----------------------

               First Anniversary of Vesting Date       25% of Option Shares

               Thereafter, monthly on the last day of each month, 1/48 of the
               Option Shares until fully vested.

                                       1
<PAGE>

               In the event of fractional Shares, the number of Shares shall be
adjusted accordingly to the nearest whole Share.

        Termination Period:

        The Option may be exercised before the end of the period ("Termination
Period") expiring thirty (30) days after termination of employment or consulting
relationship, except as set out in Sections 7 and 8 of the Terms and Conditions
(but in no event later than the Expiration Date).

        Form of Exercise:

        Exercise of this Option shall be made on a form of Exercise Notice
provided by the Company and accompanied by cash or check in the amount of the
exercise price and applicable withholding taxes.

        OPTIONEE ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO
THIS OPTION IS EARNED ONLY BY CONTINUING CONSULTANCY OR EMPLOYMENT AT THE WILL
OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR
ACQUIRING SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT
NOTHING IN THIS AGREEMENT, NOR IN THE COMPANY'S 2000 STOCK PLAN, WHICH IS
INCORPORATED HEREIN BY REFERENCE, SHALL CONFER UPON OPTIONEE ANY RIGHT WITH
RESPECT TO CONTINUATION OF EMPLOYMENT OR CONSULTANCY BY THE COMPANY, NOR SHALL
IT INTERFERE IN ANY WAY WITH THE COMPANY'S RIGHT TO TERMINATE HIS OR HER
EMPLOYMENT OR CONSULTANCY AT ANY TIME, WITH OR WITHOUT CAUSE.

        Optionee acknowledges receipt of a copy of the Plan and certain
information related to it and represents that he or she is familiar with the
terms and provisions of the Plan and this Option Agreement. Optionee accepts
this Option Agreement subject to all such terms and provisions. Optionee has
reviewed the Plan and this Option Agreement in their entirety, has had an
opportunity to obtain the advice of counsel prior to executing this Option
Agreement and fully understands all provisions of the Option Agreement.

        By your signature and the signature of the Company's representative
below, you and the Company agree that this Option is granted under and governed
by the terms and conditions of the 2000 STOCK PLAN and the Option Agreement,
each of which are attached and made a part of this document.

OPTIONEE:                                      PURPLE RAY, INC.,
                                               a California corporation

________________________________               By ______________________________
Signature

________________________________               Title ___________________________
Print Name

Dated: ___________________, 20__                Dated: ___________________, 20__

                                       2
<PAGE>

I am unmarried or reside in a separate property state ___.
Spousal consent attached ____.
I am married and have previously filed a spousal consent with the Company._____

                                CONSENT OF SPOUSE

               The undersigned spouse of Optionee has read and hereby approves
the terms and conditions of the Plan and this Option Agreement. In consideration
of the Company's granting his or her spouse the right to purchase Shares as set
forth in the Plan and this Option Agreement, the undersigned hereby agrees to be
irrevocably bound by the terms and conditions of the Plan and this Option
Agreement and any other option in which the undersigned may have an interest and
further agrees that any community property interest shall be similarly bound.
The undersigned hereby appoints the undersigned's spouse as attorney-in-fact for
the undersigned with respect to any amendment or exercise of rights under the
Plan and this Option Agreement and any other option in which the undersigned may
have an interest.

                                        ________________________________________
                                                   Spouse of Optionee

                                       3
<PAGE>

                                PURPLE RAY, INC.

                                 2000 STOCK PLAN

                    EXHIBIT A TO NOTICE OF STOCK OPTION GRANT

                 TERMS AND CONDITIONS OF STOCK OPTION AGREEMENT

1.      Grant of Option. Purple Ray, Inc., a California corporation
(the "COMPANY"), hereby grants to the Optionee (the "OPTIONEE") named in the
Notice of Stock Option Grant (the "NOTICE OF GRANT"), an option (the "OPTION")
to purchase a number of Shares, as set forth in the Notice of Grant, at the
exercise price per share set forth in the Notice of Grant (the "EXERCISE
Price"), subject to the terms, conditions and definitions of the 2000 Stock Plan
(the "PLAN") adopted by the Company, which is incorporated herein by reference.
Together, the Notice of Grant and these Terms and Conditions of Stock Option
Agreement may be referred to hereinafter as the "OPTION AGREEMENT." In the event
of a conflict between the terms and conditions of the Plan and this Option
Agreement, the Option Agreement shall prevail. Unless otherwise defined herein,
the terms defined in the Plan shall have the same defined meanings in this
Option Agreement.

         If designated in the Notice of Grant as an Incentive Stock Option, this
Option is intended to qualify as an Incentive Stock Option under Section 422 of
the Code.

2.      Exercise of Option.

        (a) Right to Exercise. This Option is exercisable during its term in
accordance with the Vesting Schedule set out in the Notice of Grant and the
applicable provisions of the Plan and this Option Agreement. In the event of
Optionee's death, Disability or other termination of Optionee's employment or
consulting relationship, the exercisability of the Option is governed by the
applicable provisions of the Plan and this Option Agreement.

        (b) Method of Exercise. This Option is exercisable by delivery of an
exercise notice, in the form provided by the Company (the "EXERCISE NOTICE"),
which shall state the election to exercise the Option, the number of Shares in
respect of which the Option is being exercised (the "EXERCISED SHARES"), and
such other representations and agreements as to the holder's investment intent
with respect to the Exercised Shares as may be required by the Company pursuant
to the provisions of the Plan. The Exercise Notice shall be signed by the
Optionee and, if required by the Company, by the Optionee's spouse, and shall be
delivered in person or by certified mail to the Secretary of the Company. The
Exercise Notice shall be accompanied by payment of the aggregate Exercise Price
as to all Exercised Shares, plus applicable withholding taxes. This Option shall
be deemed to be exercised upon receipt by the Company of such fully executed
Exercise Notice accompanied by such aggregate Exercise Price and taxes. No
Shares shall be issued pursuant to the exercise of this Option unless such
issuance and exercise complies with all relevant provisions of law and the
requirements of any stock exchange upon which the Shares are then listed.
Assuming such compliance, for income tax purposes the Exercised Shares shall be
considered transferred to the Optionee on the date the Option is exercised with
respect to such Exercised Shares.

                                       1
<PAGE>

3.      Method of Payment. Payment of the aggregate Exercise Price shall be by
any of the following, or a combination thereof, at the election of the Optionee:

        (a) cash; or

        (b) check; or

        (c) such other consideration as is indicated on the Notice of Grant.

4.      Optionee's Representations. In the event the Shares purchasable
pursuant to the exercise of this Option have not been registered under the
Securities Act of 1933, as amended, at the time this Option is exercised,
Optionee shall, if required by the Company, concurrently with the exercise of
all or any portion of this Option, deliver to the Company an Investment
Representation Statement in the form attached as EXHIBIT A to the Exercise
Notice.

5.      Restrictions on Exercise. This Option may not be exercised until such
time as the Plan has been approved by the shareholders of the Company, or if the
issuance of such Shares upon such exercise or the method of payment of
consideration for such shares would constitute a violation of any applicable
federal or state securities or other law or regulation, including any rule under
Part 207 of Title 12 of the Code of Federal Regulations ("Regulation G") as
promulgated by the Federal Reserve Board. As a condition to the exercise of this
Option, the Company may require Optionee to make any representation and warranty
to the Company as may be required by any applicable law or regulation.

6.      Termination of Relationship. In the event of termination of Optionee's
consulting relationship or Continuous Status as an Employee, Optionee may, to
the extent otherwise so entitled at the date of such termination (the
"TERMINATION DATE"), exercise this Option before the expiration of the
Termination Period set out in the Notice of Grant. To the extent that Optionee
was not entitled to exercise this Option at the Termination Date, or if Optionee
does not exercise this Option within the time specified herein, the Option shall
terminate. In the event that the Optionee is terminated for cause, the Option
shall expire on the Termination Date.

7.      Disability of Optionee. Notwithstanding the provisions of Section 6
above, in the event of termination of Optionee's Continuous Status as an
Employee as a result of disability (as determined by the Board in accordance
with the policies of the Company), Optionee may, but only within six (6) months
from the date of termination of employment (but in no event later than the date
of expiration of the term of this Option as set forth in Section 10 below),
exercise the Option to the extent otherwise so entitled at the date of such
termination. To the extent that Optionee was not entitled to exercise the Option
at the date of termination, or if Optionee does not exercise such Option (to the
extent otherwise so entitled) within the time specified herein, the Option shall
terminate.

8.      Death of Optionee. In the event of the death of Optionee, the Option
may be exercised at any time within twelve (12) months following the date of
death (but in no event later than the date of expiration of the term of this
Option as set forth in Section 10 below), by Optionee's estate or by a person
who acquired the right to exercise the

                                       2
<PAGE>

Option by bequest or inheritance, but only to the extent the Optionee could
exercise the Option at the date of death.

9.      Non-Transferability of Option. This Option may not be transferred in any
manner otherwise than by will or by the laws of descent or distribution and may
be exercised during the lifetime of Optionee only by him. The terms of this
Option shall be binding upon the executors, administrators, heirs, successors
and assigns of the Optionee.

10.     Term of Option. This Option may be exercised only within the term set
out in the Notice of Grant, and may be exercised during such term only in
accordance with the Plan and the terms of this Option. The limitations set out
in Section 7 of the Plan regarding Option terms and Options granted to more than
ten percent (10%) shareholders shall apply to this Option.

11.     Tax Consequences. Some of the federal and California tax consequences
relating to this Option, as of the date of this Option, are set forth below.
THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE
SUBJECT TO CHANGE. THE OPTIONEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING
THIS OPTION OR DISPOSING OF THE SHARES.

        (a) Exercising the Option.

            (i) Nonqualified Stock Option ("NSO"). If this Option does not
qualify as an ISO, the Optionee may incur regular federal income tax and
California income tax liability upon exercise. The Optionee will be treated as
having received compensation income (taxable at ordinary income tax rates) equal
to the excess, if any, of the fair market value of the Exercised Shares on the
date of exercise over their aggregate Exercise Price. If the Optionee is an
employee, the Company will be required to withhold from his or her compensation
or collect from Optionee and pay to the applicable taxing authorities an amount
equal to a percentage of this compensation income at the time of exercise.

            (ii) Incentive Stock Option ("ISO"). If this Option qualifies as an
ISO, the Optionee will have no regular federal income tax or California income
tax liability upon its exercise, although the excess, if any, of the fair market
value of the Exercised Shares on the date of exercise over their aggregate
Exercise Price will be treated as an adjustment to the alternative minimum tax
for federal tax purposes and may subject the Optionee to alternative minimum tax
in the year of exercise.

            (iii) California ISO's. Employees who meet certain limited-income
requirements may treat a nonqualified stock option granted before January 1,
2002 as a qualified incentive stock option for California purposes only. To
qualify, the employee must have earned income from the Company of $40,000 or
less for the taxable year in which the option is exercised. California ISO
treatment is limited annually to 1,000 shares with a value at the time the
option is issued of less than $100,000.

        (b) Disposition of Shares.

                                       3
<PAGE>

            (i) NSO. If the Optionee holds NSO Shares for at least one year, any
gain realized on disposition of the Shares will be treated as long-term capital
gain for federal income tax purposes.

            (ii) ISO. If the Optionee holds ISO Shares for at least one year
after exercise AND two years after the grant date, any gain realized on
disposition of the Shares will be treated as long-term capital gain for federal
income tax purposes. If the Optionee disposes of ISO Shares within one year
after exercise or two years after the grant date, any gain realized on such
disposition will be treated as compensation income (taxable at ordinary income
rates) to the extent of the excess, if any, of the LESSER OF (A) the difference
between the FAIR MARKET VALUE OF THE SHARES ACQUIRED ON THE DATE OF EXERCISE and
the aggregate Exercise Price, or (B) the difference between the SALE PRICE of
such Shares and the aggregate Exercise Price.

        (c) Notice of Disqualifying Disposition of ISO Shares. If the Optionee
sells or otherwise disposes of any of the Shares acquired pursuant to an ISO on
or before the later of (i) the date two years after the grant date, or (ii) the
date one year after the exercise date, the Optionee shall immediately notify the
Company in writing of such disposition. The Optionee agrees that he or she may
be subject to income tax withholding by the Company on the compensation income
recognized from such early disposition of ISO Shares by payment in cash or out
of the current earnings paid to the Optionee.

                                       4
<PAGE>

                                PURPLE RAY, INC.

                                 2000 STOCK PLAN

                        EXERCISE NOTICE FOR VESTED SHARES

Attention:  Secretary

1.      Exercise of Option. Effective as of today, ___________, 20__, the
undersigned ("Optionee") hereby elects to exercise Optionee's option to purchase
_________ shares of the Common Stock (the "SHARES") of Purple Ray, Inc. (the
"COMPANY") for $____ per Share under and pursuant to the Company's 2000 Stock
Plan, as amended (the "PLAN"), and the Notice of Stock Option Grant and Terms
and Conditions of Stock Option Agreement dated ________ (together, the "OPTION
AGREEMENT"). The total purchase price with respect to the Shares is
$________________.

2.      Representations of Optionee. Optionee acknowledges that Optionee has
received, read and understood the Plan and the Option Agreement and agrees to
abide by and be bound by their terms and conditions. Optionee represents that
Optionee is purchasing the Shares for Optionee's own account for investment and
not with a view to, or for sale in connection with, a distribution of any of
such Shares.

3.      Compliance with Securities Laws; Federal Restrictions on Transfer.
Optionee has read and executed the Investment Representation Statement attached
as EXHIBIT A hereto. Optionee represents that he or she understands the matters
set forth in the Investment Representation Statement and that he or she is
purchasing the Shares subject to the restrictions and limitations set forth in
that document.

4.      Right of First Refusal. Before any Shares held by Optionee or any
transferee (either being sometimes referred to herein as the "HOLDER") may be
sold or otherwise transferred (including transfer by gift or operation of law),
the Company or its assignee(s) shall have a right of first refusal to purchase
the Shares on the terms and conditions set forth in this Section (the "RIGHT OF
FIRST REFUSAL").

        (a) Notice of Proposed Transfer. The Holder of the Shares shall deliver
to the Company a written notice (the "SALE NOTICE") stating: (i) the Holder's
bona fide intention to sell or otherwise transfer such Shares; (ii) the name of
each proposed purchaser or other transferee ("PROPOSED TRANSFEREE"); (iii) the
number of Shares to be transferred to each Proposed Transferee; and (iv) the
bona fide cash price or other consideration for which the Holder proposes to
transfer the Shares (the "OFFERED PRICE"), and the Holder shall offer the Shares
at the Offered Price to the Company or its assignee(s).

        (b) Bona Fide Transfer. Within ten (10) days after receipt of the Sale
Notice, the Company shall determine the bona fide nature of the proposed
voluntary transfer and give the Optionee written notice of the Company's
determination. If the proposed transfer is deemed not to be bona fide, the
Optionee shall be responsible for providing additional information to the
Company to show the bona fide nature of the proposed transfer. The Company shall
have the right to demand further assurances from the

                                       1
<PAGE>

Optionee and the Proposed Transferee (in a form satisfactory to the Company)
that the Sale Notice fully and accurately sets forth all of the terms and
conditions of the proposed transfer, including, without limitation, assurance
that the Sale Notice fully and accurately sets forth the consideration actually
to be paid for the Shares and all transactions, directly or indirectly, between
the parties which may have affected the price the Proposed Transferee was
willing to pay for the Shares.

         (c) Exercise of Right of First Refusal by Company. In the event that
the proposed transfer is deemed to be bona fide, the Company and/or its
assignee(s) may, by giving written notice to the Holder, elect to purchase all,
but not less than all (unless the Holder so consents) of the Shares proposed to
be transferred to any one or more of the Proposed Transferees, at the purchase
price determined in accordance with subsection (d) below. Such written notice
may be given within thirty (30) days after receipt of the Sale Notice.

         (d) Purchase Price. The purchase price ("PURCHASE PRICE") for the
Shares purchased by the Company or its assignee(s) under this Section shall be
the Offered Price. If the Offered Price includes consideration other than cash,
the cash equivalent value of the non-cash consideration shall be determined by
the Board of Directors of the Company in good faith.

         (e) Payment. Payment of the Purchase Price shall be made, at the option
of the Company or its assignee(s), by cash, check, cancellation of all or a
portion of any outstanding indebtedness of the Holder to the Company (or, in the
case of repurchase by an assignee, to the assignee), or by any combination
thereof within sixty (60) days after receipt of the Sale Notice, in the manner
and at the times set forth in such notice.

        (f) Holder's Right to Transfer. If all of the Shares proposed in the
Notice to be transferred to a given Proposed Transferee are not purchased by the
Company and/or its assignee(s), then the Holder may sell or otherwise transfer
such Shares to that Proposed Transferee at the Offered Price or at a higher
price, provided that such sale or other transfer is consummated within one
hundred twenty (120) days after the date of the Notice and provided further that
any such sale or other transfer is effected in accordance with any applicable
securities laws and the Proposed Transferee agrees in writing that the
provisions of this Section shall continue to apply to the Shares in the hands of
such Proposed Transferee. If the Shares described in the Notice are not
transferred to the Proposed Transferee within such period, a new Notice shall be
given to the Company, and the Company and/or its assignees shall again be
offered the Right of First Refusal before any Shares held by the Holder may be
sold or otherwise transferred.

        (g) Exception for Certain Family Transfers. Anything to the contrary
contained in this Section notwithstanding, the transfer of any or all of the
Shares during the Optionee's lifetime or on the Optionee's death by will or
intestacy to the Optionee's immediate family or a trust for the benefit of the
Optionee's immediate family shall be exempt from the provisions of this Section.
"Immediate Family" as used herein shall mean spouse, lineal descendant or
antecedent, father, mother, brother or sister. In such case, the transferee or
other recipient shall receive and hold the Shares so transferred subject to the
provisions of this Section, and there shall be no further transfer of such
Shares except in accordance with the terms of this Section.

                                       2
<PAGE>

        (h) Transfers Not Subject to the Right of First Refusal. The Right of
First Refusal shall not apply to any transfer or exchange of the shares acquired
pursuant to the exercise of the Option Agreement if such transfer is in
connection with a Change in Capitalization, as described in Section 12 of the
Plan. If the consideration received pursuant to such transfer or exchange
consists of stock of a Parent or Subsidiary, such consideration shall remain
subject to the Right of First Refusal unless the provisions of paragraph 4(j)
result in a termination of the Right of First Refusal.

        (i) Assignment of the Right of First Refusal. The Company shall have the
right to assign the Right of First Refusal at any time, whether or not the
Optionee has attempted a transfer, to one or more persons as may be selected by
the Company.

        (j) Early Termination of the Right of Refusal. The other provisions of
this paragraph 4 notwithstanding, the Right of First Refusal shall terminate,
and be of no further force and effect upon (i) a merger of the Company or
transaction in which over 80% of the voting power of the Company is transferred
and following which the shareholders of the Company have less than 20% of the
voting power of the resulting or combined entity and shall not apply with
respect to shares sold in such offering or acquisition, or (ii) the existence of
a public market for the class of shares subject to the Right of First Refusal. A
"public market" shall be deemed to exist if (x) such stock is listed on a
national securities exchange (as that term is used in the Exchange Act) or (y)
such stock is traded on the over-the-counter market and prices therefor are
published daily on business days in a recognized financial journal.

5.      Rights as Shareholder. Subject to the terms and conditions of this
Agreement, Optionee shall have all of the rights of a shareholder of the Company
with respect to the Shares from and after the date that Optionee delivers full
payment of the Exercise Price until such time as Optionee disposes of the Shares
or the Company and/or its assignee(s) exercises the Right of First Refusal
hereunder. Upon such exercise, Optionee shall have no further rights as a holder
of the Shares so purchased except the right to receive payment for the Shares so
purchased in accordance with the provisions of this Agreement, and Optionee
shall forthwith cause the certificate(s) evidencing the Shares so purchased to
be surrendered to the Company for transfer or cancellation.

6.      Tax Consultation. Optionee understands that Optionee may suffer adverse
tax consequences as a result of Optionee's purchase or disposition of the
Shares. Optionee represents that Optionee has consulted with any tax consultants
Optionee deems advisable in connection with the purchase or disposition of the
Shares and that Optionee is not relying on the Company for any tax advice.

7.      Restrictive Legends and Stop-Transfer Orders.

        (a) Legends. Optionee understands and agrees that the Company shall
cause the legends set forth below or legends substantially equivalent thereto,
to be placed upon any certificate(s) evidencing ownership of the Shares together
with any other legends that may be required by state or federal securities laws:

         THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
         SECURITIES ACT OF 1933 (THE "ACT") AND MAY NOT BE OFFERED, SOLD OR
         OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL
         REGISTERED

                                       3
<PAGE>

         UNDER THE ACT OR, IN THE OPINION OF COUNSEL IN FORM AND SUBSTANCE
         SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR
         TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.

         THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
         RESTRICTIONS ON TRANSFER AND RIGHT OF FIRST REFUSAL OPTIONS HELD BY THE
         ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE BETWEEN
         THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY
         BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER
         RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON TRANSFEREES OF
         THESE SHARES.

         Optionee understands that transfer of the Shares may be restricted by
Section 260.141.11 of the Rules of the California Corporations Commissioner. In
the event such a restriction is required by the state of California, a copy of
the Commissioner"s Rules will be furnished to Optionee and an additional legend
may be required on the Shares.

        (b) Stop-Transfer Notices. Optionee agrees that, in order to ensure
compliance with the restrictions referred to herein, the Company may issue
appropriate "stop transfer" instructions to its transfer agent, if any, and
that, if the Company transfers its own securities, it may make appropriate
notations to the same effect in its own records.

        (c) Refusal to Transfer. The Company shall not be required (i) to
transfer on its books any Shares that have been sold or otherwise transferred in
violation of any of the provisions of this Agreement or (ii) to treat as owner
of such Shares or to accord the right to vote or pay dividends to any purchaser
or other transferee to whom such Shares shall have been so transferred.

8.      Market Standoff Agreement. Optionee hereby agrees that if so requested
by the Company or any representative of the underwriters in connection with any
registration of the offering of any securities of the Company under the 1933
Act, Optionee shall not sell or otherwise transfer any Shares or other
securities of the Company during the 180-day period following the effective date
of a registration statement of the Company filed under the 1933 Act; provided,
however, that such restriction shall only apply to the first registration
statement of the Company to become effective under the 1933 Act which include
securities to be sold on behalf of the Company to the public in an underwritten
public offering under the 1933 Act. The Company may impose stop-transfer
instructions with respect to securities subject to the foregoing restrictions
until the end of such 180-day period.

9.      Successors and Assigns. The Company may assign any of its rights under
this Agreement to single or multiple assignees, and this Agreement shall inure
to the benefit of the successors and assigns of the Company. Subject to the
restrictions on transfer herein set forth, this Agreement shall be binding upon
Optionee and his or her heirs, executors, administrators, successors and
assigns.

                                       4
<PAGE>

10.     Interpretation. Any dispute regarding the interpretation of this
Agreement shall be submitted by Optionee or by the Company forthwith to the Plan
Administrator which shall review such dispute at its next regular meeting. The
resolution of such a dispute by the Administrator shall be final and binding on
the Company and on Optionee.

11.     Governing Law; Severability. This Agreement shall be governed by and
construed in accordance with the laws of the State of California excluding that
body of law pertaining to conflicts of law. Should any provision of this
Agreement be determined by a court of law to be illegal or unenforceable, the
other provisions shall nevertheless remain effective and shall remain
enforceable.

12.     Notices. Any notice required or permitted hereunder shall be given in
writing and shall be deemed effectively given upon personal delivery or upon
deposit in the United States mail by certified mail, with postage and fees
prepaid, addressed to the other party at its address as shown below beneath its
signature, or to such other address as such party may designate in writing from
time to time to the other party.

13.     Further Instruments. The parties agree to execute such further
instruments and to take such further action as may be reasonably necessary to
carry out the purposes and intent of this Agreement.

14.     Delivery of Payment. Optionee herewith delivers to the Company the full
Exercise Price for the Shares.

15.     Entire Agreement. The Plan and Option Agreement are incorporated herein
by reference. This Agreement, the Plan and the Option Agreement constitute the
entire agreement of the parties and supersede in their entirety all prior
undertakings and agreements of the Company and Optionee with respect to the
subject matter hereof, and is governed by California law except for that body of
law pertaining to conflict of laws.

Submitted by:                                  Accepted by:

PURCHASER:                                     PURPLE RAY, INC.,
                                               a California corporation

___________________________________            By ______________________________
              (Signature)
                                               Its _____________________________

Address

                                       5
<PAGE>

                                PURPLE RAY, INC.

                                 2000 STOCK PLAN

                          EXHIBIT A TO EXERCISE NOTICE

                       INVESTMENT REPRESENTATION STATEMENT

OPTIONEE    :

COMPANY     :    PURPLE RAY, INC.

SECURITY    :    COMMON STOCK

AMOUNT      :

DATE        :

In connection with the purchase of the above-listed Securities, the undersigned
Optionee represents to the Company the following:

        (a) Optionee is aware of the Company's business affairs and financial
condition and has acquired sufficient information about the Company to reach an
informed and knowledgeable decision to acquire the securities. Optionee is
acquiring these securities for investment for Optionee's own account only and
not with a view to, or for resale in connection with, any "distribution" thereof
within the meaning of the Securities Act of 1933, as amended (the "Securities
Act").

        (b) Optionee acknowledges and understands that the securities constitute
"restricted securities" under the Securities Act and have not been registered
under the Securities Act in reliance upon a specific exemption therefrom, which
exemption depends upon, among other things, the bona fide nature of Optionee's
investment intent as expressed herein. In this connection, Optionee understands
that, in the view of the Securities and Exchange Commission, the statutory basis
for such exemption may be unavailable if Optionee's representation was
predicated solely upon a present intention to hold these Securities for the
minimum capital gains period specified under tax statutes, for a deferred sale,
for or until an increase or decrease in the market price of the Securities, or
for a period of one year or any other fixed period in the future. Optionee
further understands that the Securities must be held indefinitely unless they
are subsequently registered under the Securities Act or an exemption from such
registration is available. Optionee further acknowledges and understands that
the Company is under no obligation to register the securities. Optionee
understands that the certificate evidencing the securities will be imprinted
with a legend which prohibits the transfer of the Securities unless they are
registered or such registration is not required in the opinion of counsel
satisfactory to the Company and any other legend required under applicable state
securities laws.

(c) Optionee is familiar with the provisions of Rule 701 and Rule 144, each
promulgated under the Securities Act, which, in substance, permit limited public
resale of "restricted securities" acquired, directly or indirectly from the
issuer thereof, in a non-public offering subject to the satisfaction of certain
conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the
time of exercise of the Option by the Optionee,

                                       1
<PAGE>

such exercise will be exempt from registration under the Securities Act. In the
event the Company later becomes subject to the reporting requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, ninety (90) days thereafter
the securities exempt under Rule 701 may be resold, subject to the satisfaction
of certain of the conditions specified by Rule 144, including among other
things: (1) the sale being made through a broker in an unsolicited "broker's
transaction" or in transactions directly with a market maker (as said term is
defined under the Securities Exchange Act of 1934); and, in the case of an
affiliate, (2) the availability of certain public information about the Company,
and the amount of securities being sold during any three month period not
exceeding the limitations specified in Rule 144(e), if applicable.

In the event that the Company does not qualify under Rule 701 at the time of
exercise of the Option, then the securities may be resold in certain limited
circumstances subject to the provisions of Rule 144, which requires among other
things: (1) the resale occurring not less than one year after the party has
purchased, and made full payment for, within the meaning of Rule 144, the
securities to be sold; and, in the case of an affiliate, or of a non-affiliate
who has held the securities less than two years, (2) the availability of certain
public information about the Company, (3) the sale being made through a broker
in an unsolicited "broker's transaction" or in transactions directly with a
market maker (as said term is defined under the Securities Exchange Act of
1934), and (4) the amount of securities being sold during any three month period
not exceeding the specified limitations stated therein, if applicable.

        (d) Optionee agrees, in connection with the Company's initial
underwritten public offering of the Company's securities, (1) not to sell, make
short sale of, loan, grant any options for the purchase of, or otherwise dispose
of any shares of Common Stock of the Company held by Optionee (other than those
shares included in the registration) without the prior written consent of the
Company or the underwriters managing such initial underwritten public offering
of the Company's securities for one hundred eighty (180) days from the effective
date of such registration, and (2) further agrees to execute any agreement
reflecting (1) above as may be requested by the underwriters at the time of the
public offering; provided however that the officers and directors of the Company
who own the stock of the Company also agree to such restrictions.

        (e) Optionee further understands that in the event all of the applicable
requirements of Rule 701 or 144 are not satisfied, registration under the
Securities Act, compliance with Regulation A, or some other registration
exemption will be required; and that, notwithstanding the fact that Rules 144
and 701 are not exclusive, the Staff of the Securities and Exchange Commission
has expressed its opinion that persons proposing to sell private placement
securities other than in a registered offering and otherwise than pursuant to
Rules 144 or 701 will have a substantial burden of proof in establishing that an
exemption from registration is available for such offers or sales, and that such
persons and their respective brokers who participate in such transactions do so
at their own risk. Optionee understands that no assurances can be given that any
such other registration exemption will be available in such event.

                                       2
<PAGE>

        (f) Optionee understands that the certificate evidencing the Securities
may be imprinted, if required by the state of California, with a legend which
prohibits the transfer of the Securities without the consent of the Commissioner
of Corporations of California. At the time of exercise, Optionee will be
furnished with a copy of the applicable Commissioner's Rules with respect to
such restriction, if any.

                                    Signature of Optionee:

                                    ____________________________________________

                                    Date: ________________, 20__

                                       3
<PAGE>

                                PURPLE RAY, INC.

                                 2000 STOCK PLAN

                     EXERCISE NOTICE FOR UNVESTED SHARES AND
                           RESTRICTED STOCK AGREEMENT

Secretary
Purple Ray, Inc.

_______________________

Dear Sir:

1.      Exercise of Option. Effective as of today, ___________, 20__, the
undersigned ("OPTIONEE") hereby elects to exercise Optionee's option to purchase
_________ shares of the Common Stock (the "SHARES") of Purple Ray, Inc. (the
"COMPANY") under and pursuant to the Company's Stock Plan, as amended (the
"PLAN") and the Notice of Stock Option Grant and Terms and Conditions of Stock
Option Agreement dated __________,20__ (together, the "OPTION AGREEMENT"). Of
these Shares, Optionee has elected to purchase __________ of those Shares which
have become vested under the Vesting Schedule set out in the Notice of Grant
(the "VESTED SHARES") and __________ Shares which have not yet vested under such
schedule (the "UNVESTED SHARES"). The Purchase Price for the Shares shall be
$______ per Share, as set out in the Notice of Grant, for an aggregate Purchase
Price of $_________.

2.      Representations of Optionee. Optionee acknowledges that Optionee has
received, read and understood the Plan and the Option Agreement and agrees to
abide by and be bound by their terms and conditions. Optionee represents that
Optionee is purchasing the Shares for Optionee's own account for investment and
not with a view to, or for sale in connection with, a distribution of any of
such Shares.

3.      Compliance with Securities Laws; Federal Restrictions on Transfer.
Optionee has read and executed the Investment Representation Statement attached
as EXHIBIT A hereto. Optionee represents that he or she understands the matters
set forth in the Investment Representation Statement and that he or she is
purchasing the Shares subject to the restrictions and limitations set forth in
that document.

4.      Company's Repurchase Option. The Company or its assignee(s) shall have
the option to repurchase any or all of the Unvested Shares on the terms and
conditions set forth in this section (the "REPURCHASE OPTION") if the Optionee
should cease to be "employed" by the Company (as defined in section 4(a) below)
for any reason or no reason, including without limitation death, disability,
voluntary resignation or termination by the Company with or without cause.

        (a) Right of Termination Unaffected. Nothing in this Agreement shall be
construed to limit or otherwise affect in any manner whatsoever the right or
power of the Company to terminate Optionee's employment at any time for any
reason or no reason, with or without cause. Optionee shall be considered to be
employed by the Company if Optionee is an officer, director or full-time
employee of the Company or any Parent or Subsidiary of the Company (as defined
in the Plan) or if the Board of Directors determines that Optionee is rendering
substantial services as a part-time employee, consultant or independent
contractor to the Company or any Parent or Subsidiary of the

                                       4
<PAGE>

Company (as defined in the Plan). In case of any dispute, the Board of Directors
of the Company shall have discretion to determine (i) whether Optionee has
ceased to be employed by the Company and (ii) the date on which the employment
relationship ceases (the "TERMINATION DATE").

       (b) Exercise of Repurchase Option. At any time within ninety (90) days
after Optionee's Termination Date, the Company or its assignee(s) may elect to
repurchase any or all shares that are Unvested Shares as of the Termination Date
and that were purchased pursuant to the Option Agreement by giving Optionee (or
Optionee's personal representative as the case may be) written notice of
exercise of the Repurchase Option.

            (i) Repurchase Price. The Company or its assignee(s) shall have the
option to repurchase from Optionee any or all of the Unvested Shares (or from
Optionee's personal representative as the case may be) at the Exercise Price (as
defined in the Option Agreement), as such price may be adjusted from time to
time to reflect any subsequent stock dividend, stock split, reverse stock split
or recapitalization of the Company (the "REPURCHASE PRICE").

            (ii) Payment of Repurchase Price. The Repurchase Price shall be
payable, at the option of the Company or its assignee(s), by cash, check or by
cancellation of all or a portion of any outstanding indebtedness of Optionee to
the Company (or, in the case of repurchase by an assignee, to the assignee) or
any combination thereof. The Repurchase Price shall be paid without interest
within 90 days after the Termination Date.

            (iii) Lapse of Repurchase Option. Starting on the Date of Grant and
ending on the Termination Date, all Unvested Shares held by the Optionee shall
be released from the Company's Repurchase Option and cease to be Unvested Shares
according to the Vesting Schedule set out in the Notice of Grant.

5.      Right of First Refusal. Before any Shares held by Optionee or any
transferee (either being sometimes referred to herein as the "HOLDER") may be
sold or otherwise transferred (including transfer by gift or operation of law),
the Company or its assignee(s) shall have a right of first refusal to purchase
the Shares on the terms and conditions set forth in this Section (the "RIGHT OF
FIRST REFUSAL").

       (a) Notice of Proposed Transfer. The Holder of the Shares shall deliver
to the Company a written notice (the "SALE NOTICE") stating: (i) the Holder's
bona fide intention to sell or otherwise transfer such Shares; (ii) the name of
each proposed purchaser or other transferee ("PROPOSED TRANSFEREE"); (iii) the
number of Shares to be transferred to each Proposed Transferee; and (iv) the
bona fide cash price or other consideration for which the Holder proposes to
transfer the Shares (the "OFFERED PRICE"), and the Holder shall offer the Shares
at the Offered Price to the Company or its assignee(s).

       (b) Bona Fide Transfer. Within ten (10) days after receipt of the Sale
Notice, the Company shall determine the bona fide nature of the proposed
voluntary transfer and give the Optionee written notice of the Company's
determination. If the proposed transfer is deemed not to be bona fide, the
Optionee shall be responsible for providing additional information to the
Company to show the bona fide nature of the proposed transfer. The Company shall
have the right to demand further assurances from the

                                       5
<PAGE>

Optionee and the Proposed Transferee (in a form satisfactory to the Company)
that the Sale Notice fully and accurately sets forth all of the terms and
conditions of the proposed transfer, including, without limitation, assurance
that the Sale Notice fully and accurately sets forth the consideration actually
to be paid for the Shares and all transactions, directly or indirectly, between
the parties which may have affected the price the Proposed Transferee was
willing to pay for the Shares.

        (c) Exercise of Right of First Refusal by Company. In the event that the
proposed transfer is deemed to be bona fide, the Company and/or its assignee(s)
may, by giving written notice to the Holder, elect to purchase any or all of the
Shares proposed to be transferred to any one or more of the Proposed
Transferees, at the purchase price determined in accordance with subsection (c)
below. Such written notice may be given within thirty (30) days after receipt of
the Sale Notice.

        (d) Purchase Price. The purchase price ("PURCHASE PRICE") for the Shares
purchased by the Company or its assignee(s) under this Section shall be the
Offered Price. If the Offered Price includes consideration other than cash, the
cash equivalent value of the non-cash consideration shall be determined by the
Board of Directors of the Company in good faith.

        (e) Payment. Payment of the Purchase Price shall be made, at the option
of the Company or its assignee(s), by cancellation of all or a portion of any
outstanding indebtedness of the Holder to the Company (or, in the case of
repurchase by an assignee, to the assignee), or by any combination thereof
within sixty (60) days after receipt of the Sale Notice, in the manner and at
the times set forth in such notice.

        (f) Holder's Right to Transfer. If all of the Shares proposed in the
Notice to be transferred to a given Proposed Transferee are not purchased by the
Company and/or its assignee(s), then the Holder may sell or otherwise transfer
such Shares to that Proposed Transferee at the Offered Price or at a higher
price, provided that such sale or other transfer is consummated within one
hundred twenty (120) days after the date of the Notice and provided further that
any such sale or other transfer is effected in accordance with any applicable
securities laws and the Proposed Transferee agrees in writing that the
provisions of this Section shall continue to apply to the Shares in the hands of
such Proposed Transferee. If the Shares described in the Notice are not
transferred to the Proposed Transferee within such period, a new Notice shall be
given to the Company, and the Company and/or its assignees shall again be
offered the Right of First Refusal before any Shares held by the Holder may be
sold or otherwise transferred.

        (g) Exception for Certain Family Transfers. Anything to the contrary
contained in this Section notwithstanding, the transfer of any or all of the
Shares during the Optionee's lifetime or on the Optionee's death by will or
intestacy to the Optionee's immediate family or a trust for the benefit of the
Optionee's immediate family shall be exempt from the provisions of this Section.
"Immediate Family" as used herein shall mean spouse, lineal descendant or
antecedent, father, mother, brother or sister. In such case, the transferee or
other recipient shall receive and hold the Shares so transferred subject to the
provisions of this Section, and there shall be no further transfer of such
Shares except in accordance with the terms of this Section.

                                       6
<PAGE>

        (h) Transfers Not Subject to the Right of First Refusal. The Right of
First Refusal shall not apply to any transfer or exchange of the shares acquired
pursuant to the exercise of the Option Agreement if such transfer is in
connection with a Change in Capitalization, as described in Section 13 of the
Plan. If the consideration received pursuant to such transfer or exchange
consists of stock of a Parent or Subsidiary, such consideration shall remain
subject to the Right of First Refusal unless the provisions of paragraph 5(j)
result in a termination of the Right of First Refusal.

        (i) Assignment of the Right of First Refusal. The Company shall have the
right to assign the Right of First Refusal at any time, whether or not the
Optionee has attempted a transfer, to one or more persons as may be selected by
the Company.

        (j) Early Termination of the Right of Refusal. The other provisions of
this paragraph 5 notwithstanding, the Right of First Refusal shall terminate,
and be of no further force and effect upon (i) a merger of the Company or
transaction in which over 80% of the voting power of the Company is transferred
and following which the shareholders of the Company have less than 20% of the
voting power of the resulting or combined entity and shall not apply with
respect to shares sold in such offering or acquisition, or (ii) the existence of
a public market for the class of shares subject to the Right of First Refusal. A
"public market" shall be deemed to exist if (x) such stock is listed on a
national securities exchange (as that term is used in the Exchange Act) or (y)
such stock is traded on the over-the-counter market and prices therefor are
published daily on business days in a recognized financial journal.

6.      Escrow. As security for the faithful performance of this Agreement,
Optionee agrees, immediately upon receipt of the certificate(s) evidencing the
Shares, to deliver such certificate(s), together with a stock power in the form
of ATTACHMENT 1 attached hereto, executed by Optionee and by Optionee's spouse,
if any (with the date and number of Shares left blank), to the Secretary of the
Company or its designee ("Escrow Holder"), who is hereby appointed to hold such
certificate(s) and stock power in escrow and to take all such actions and to
effectuate all such transfers and/or releases of such Shares as are in
accordance with the terms of this Agreement. Such appointment shall be evidenced
by an executed form of Joint Escrow Instructions, attached hereto as ATTACHMENT
2. Optionee and the Company agree that Escrow Holder shall not be liable to any
party to this Agreement (or to any other party) for any actions or omissions
unless Escrow Holder is grossly negligent relative thereto. The Escrow Holder
may rely upon any letter, notice or other document executed by any signature
purported to be genuine and may rely on advice of counsel and obey any order of
any court with respect to the transactions contemplated herein. The Shares shall
be released from escrow upon termination of both the Repurchase Option and the
Right of First Refusal; provided, however, that such release shall not affect
the rights of the Company with respect to any pledge of Shares to the Company.

7.      Rights as Shareholder. Subject to the terms and conditions of this
Agreement, Optionee shall have all of the rights of a shareholder of the Company
with respect to the Shares from and after the date that Optionee delivers full
payment of the Exercise Price until such time as Optionee disposes of the Shares
or the Company and/or its assignee(s) exercises the Repurchase Option or Right
of First Refusal hereunder. Upon such exercise, Optionee shall have no further
rights as a holder of the Shares so purchased except the right to receive
payment for the Shares so purchased in accordance with the provisions of this
Agreement, and Optionee shall forthwith cause

                                       7
<PAGE>

the certificate(s) evidencing the Shares so purchased to be surrendered to the
Company for transfer or cancellation.

8.      Tax Consequences.

        (a) Tax Consultation. Optionee understands that Optionee may suffer
adverse tax consequences as a result of Optionee's purchase or disposition of
the Shares. Optionee represents that Optionee has consulted with any tax
consultants Optionee deems advisable in connection with the purchase or
disposition of the Shares and that Optionee is not relying on the Company for
any tax advice.

        (b) Section 83(b) Election For Alternative Minimum Tax for Incentive
Stock Options. If the Option being exercised is an incentive stock option,
Optionee hereby acknowledges that Optionee has been informed that, with respect
to the exercise of any incentive stock option, unless an election is filed by
the Optionee with the Internal Revenue Service within thirty (30) days of the
purchase of the Shares, electing pursuant to Section 83(b) of the Internal
Revenue Code of 1986, as amended (and similar state tax provisions if
applicable) to be taxed currently for alternative minimum tax purposes on any
difference between the purchase price of the Shares and their fair market value
on the date of purchase, the Optionee will be required to include (for
alternative minimum tax purposes only) an amount equal to the excess, if any, of
the fair market value of the Shares, at the time the Company's Repurchase Option
lapses over the purchase price for such Shares. Optionee represents that
Optionee has consulted any tax consultant(s) Optionee deems advisable in
connection with the purchase of the Shares or the filing of the Election for
alternative minimum tax purposes under Section 83(b) and similar tax provisions.
A form of Election Under Section 83(b) is attached hereto as ATTACHMENT 3 for
reference. OPTIONEE HEREBY ASSUMES ALL RESPONSIBILITY FOR FILING SUCH ELECTION
AND PAYING ANY TAXES RESULTING FROM SUCH ELECTION OR THE LAPSE OF THE REPURCHASE
RESTRICTIONS ON THE SHARES.

        (c) Section 83(b) Election For Nonstatutory Stock Options. If the Option
being exercised is a nonstatutory stock option, Optionee hereby acknowledges
that Optionee has been informed that, with respect to the exercise of any
nonstatutory stock option, unless an election is filed by the Optionee with the
Internal Revenue Service within thirty (30) days of the purchase of the Shares,
electing pursuant to Section 83(b) of the Internal Revenue Code of 1986, as
amended (and similar state tax provisions if applicable) to be taxed currently
for income tax purposes on any difference between the purchase price of the
Shares and their fair market value on the date of purchase, the Optionee will be
required to include in income an amount equal to the excess, if any, of the fair
market value of the Shares, at the time the Company's Repurchase Option lapses
over the purchase price for such Shares. Optionee represents that Optionee has
consulted any tax consultant(s) Optionee deems advisable in connection with the
purchase of the Shares or the filing of the Election under Section 83(b) and
similar tax provisions. A form of Election Under Section 83(b) is attached
hereto as ATTACHMENT 3A for reference. OPTIONEE HEREBY ASSUMES ALL
RESPONSIBILITY FOR FILING SUCH ELECTION AND PAYING ANY TAXES RESULTING FROM SUCH
ELECTION OR THE LAPSE OF THE REPURCHASE RESTRICTIONS ON THE SHARES.

                                       8
<PAGE>

9.      Restrictive Legends and Stop-Transfer Orders.

        (a) Legends. Optionee understands and agrees that the Company shall
cause the legends set forth below or legends substantially equivalent thereto,
to be placed upon any certificate(s) evidencing ownership of the Shares together
with any other legends that may be required by state or federal securities laws:

        THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE "ACT") AND MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT
OR, IN THE OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER
OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN
COMPLIANCE THEREWITH.

        THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
RESTRICTIONS ON TRANSFER AND RIGHT OF REPURCHASE AND RIGHT OF FIRST REFUSAL
OPTIONS HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE
NOTICE AND RESTRICTED STOCK AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER
OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE
ISSUER. SUCH TRANSFER RESTRICTIONS, RIGHT OF REPURCHASE AND RIGHT OF FIRST
REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES.

        Optionee understands that transfer of the Shares may be restricted by
Section 260.141.11 of the Rules of the California Corporations Commissioner. In
the event such a restriction is required by the state of California, a copy of
the Commissioner"s Rules will be furnished to Optionee and an additional legend
may be required on the Shares.

            (i) Stop-Transfer Notices. Optionee agrees that, in order to ensure
compliance with the restrictions referred to herein, the Company may issue
appropriate "stop transfer" instructions to its transfer agent, if any, and
that, if the Company transfers its own securities, it may make appropriate
notations to the same effect in its own records.

            (ii) Refusal to Transfer. The Company shall not be required (A) to
transfer on its books any Shares that have been sold or otherwise transferred in
violation of any of the provisions of this Agreement or (B) to treat as owner of
such Shares or to accord the right to vote or pay dividends to any purchaser or
other transferee to whom such Shares shall have been so transferred.

10.     Market Standoff Agreement. Optionee hereby agrees that if so requested
by the Company or any representative of the underwriters in connection with any
registration of the offering of any securities of the Company under the 1933
Act, Optionee shall not sell or otherwise transfer any Shares or other
securities of the Company during the one hundred eighty (180) day period
following the effective date of a registration statement of the Company filed
under the 1933 Act; provided, however, that such restriction shall only apply to
the first registration statement of the Company to become effective under the

                                       9
<PAGE>

1933 Act which include securities to be sold on behalf of the Company to the
public in an underwritten public offering under the 1933 Act. The Company may
impose stop-transfer instructions with respect to securities subject to the
foregoing restrictions until the end of such one hundred eighty (180) day
period.

11.     Successors and Assigns. The Company may assign any of its rights under
this Agreement to single or multiple assignees, and this Agreement shall inure
to the benefit of the successors and assigns of the Company. Subject to the
restrictions on transfer herein set forth, this Agreement shall be binding upon
Optionee and his or her heirs, executors, administrators, successors and
assigns.

12.     Interpretation. Any dispute regarding the interpretation of this
Agreement shall be submitted by Optionee or by the Company forthwith to the Plan
Administrator which shall review such dispute at its next regular meeting. The
resolution of such a dispute by the Administrator shall be final and binding on
the Company and on Optionee.

13.     Governing Law; Severability. This Agreement shall be governed by and
construed in accordance with the laws of the State of California, excluding that
body of law pertaining to conflicts of law. Should any provision of this
Agreement be determined by a court of law to be illegal or unenforceable, the
other provisions shall nevertheless remain effective and shall remain
enforceable.

14.     Notices. Any notice required or permitted hereunder shall be given in
writing and shall be deemed effectively given upon personal delivery or upon
deposit in the United States mail by certified mail, with postage and fees
prepaid, addressed to the other party at its address as shown below beneath its
signature, or to such other address as such party may designate in writing from
time to time to the other party.

15.     Further Instruments. The parties agree to execute such further
instruments and to take such further action as may be reasonably necessary to
carry out the purposes and intent of this Agreement.

16.     Delivery of Payment. Optionee herewith delivers to the Company the full
Exercise Price for the Shares.

                                       10
<PAGE>

17.     Entire Agreement. The Plan and Option Agreement are incorporated herein
by reference. This Agreement, the Plan and the Option Agreement constitute the
entire agreement of the parties and supersede in their entirety all prior
undertakings and agreements of the Company and Optionee with respect to the
subject matter hereof, and is governed by California law except for that body of
law pertaining to conflict of laws.

Submitted by:                          Accepted by:

PURCHASER:                             PURPLE RAY, INC.

________________________________       By ______________________________________
          (Signature)
                                       Its _____________________________________

Address:                               Address:

                                       11
<PAGE>

                                PURPLE RAY, INC.

                                 2000 STOCK PLAN

                          EXHIBIT A TO EXERCISE NOTICE

                       INVESTMENT REPRESENTATION STATEMENT

OPTIONEE          :

COMPANY           :       PURPLE RAY, INC.

SECURITY          :       COMMON STOCK

AMOUNT            :

DATE              :

In connection with the purchase of the above-listed Securities, the undersigned
Optionee represents to the Company the following:

        (a) Optionee is aware of the Company's business affairs and financial
condition and has acquired sufficient information about the Company to reach an
informed and knowledgeable decision to acquire the securities. Optionee is
acquiring these securities for investment for Optionee's own account only and
not with a view to, or for resale in connection with, any "distribution" thereof
within the meaning of the Securities Act of 1933, as amended (the "Securities
Act").

        (b) Optionee acknowledges and understands that the securities constitute
"restricted securities" under the Securities Act and have not been registered
under the Securities Act in reliance upon a specific exemption therefrom, which
exemption depends upon, among other things, the bona fide nature of Optionee's
investment intent as expressed herein. In this connection, Optionee understands
that, in the view of the Securities and Exchange Commission, the statutory basis
for such exemption may be unavailable if Optionee's representation was
predicated solely upon a present intention to hold these Securities for the
minimum capital gains period specified under tax statutes, for a deferred sale,
for or until an increase or decrease in the market price of the Securities, or
for a period of one year or any other fixed period in the future. Optionee
further understands that the Securities must be held indefinitely unless they
are subsequently registered under the Securities Act or an exemption from such
registration is available. Optionee further acknowledges and understands that
the Company is under no obligation to register the securities. Optionee
understands that the certificate evidencing the securities will be imprinted
with a legend which prohibits the transfer of the Securities unless they are
registered or such registration is not required in the opinion of counsel
satisfactory to the Company and any other legend required under applicable state
securities laws.

        (c) Optionee is familiar with the provisions of Rule 701 and Rule 144,
each promulgated under the Securities Act, which, in substance, permit limited
public resale of "restricted securities" acquired, directly or indirectly from
the issuer thereof, in a non-

<PAGE>

public offering subject to the satisfaction of certain conditions. Rule 701
provides that if the issuer qualifies under Rule 701 at the time of exercise of
the Option by the Optionee, such exercise will be exempt from registration under
the Securities Act. In the event the Company later becomes subject to the
reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, ninety (90) days thereafter the securities exempt under Rule 701 may be
resold, subject to the satisfaction of certain of the conditions specified by
Rule 144, including among other things: (1) the sale being made through a broker
in an unsolicited "broker's transaction" or in transactions directly with a
market maker (as said term is defined under the Securities Exchange Act of
1934); and, in the case of an affiliate, (2) the availability of certain public
information about the Company, and the amount of securities being sold during
any three month period not exceeding the limitations specified in Rule 144(e),
if applicable.

In the event that the Company does not qualify under Rule 701 at the time of
exercise of the Option, then the securities may be resold in certain limited
circumstances subject to the provisions of Rule 144, which requires among other
things: (1) the resale occurring not less than one year after the party has
purchased, and made full payment for, within the meaning of Rule 144, the
securities to be sold; and, in the case of an affiliate, or of a non-affiliate
who has held the securities less than two years, (2) the availability of certain
public information about the Company, (3) the sale being made through a broker
in an unsolicited "broker's transaction" or in transactions directly with a
market maker (as said term is defined under the Securities Exchange Act of
1934), and (4) the amount of securities being sold during any three month period
not exceeding the specified limitations stated therein, if applicable.

        (d) Optionee agrees, in connection with the Company's initial
underwritten public offering of the Company's securities, (1) not to sell, make
short sale of, loan, grant any options for the purchase of, or otherwise dispose
of any shares of Common Stock of the Company held by Optionee (other than those
shares included in the registration) without the prior written consent of the
Company or the underwriters managing such initial underwritten public offering
of the Company's securities for one hundred eighty (180) days from the effective
date of such registration, and (2) further agrees to execute any agreement
reflecting (1) above as may be requested by the underwriters at the time of the
public offering; provided however that the officers and directors of the Company
who own the stock of the Company also agree to such restrictions.

        (e) Optionee further understands that in the event all of the applicable
requirements of Rule 701 or 144 are not satisfied, registration under the
Securities Act, compliance with Regulation A, or some other registration
exemption will be required; and that, notwithstanding the fact that Rules 144
and 701 are not exclusive, the Staff of the Securities and Exchange Commission
has expressed its opinion that persons proposing to sell private placement
securities other than in a registered offering and otherwise than pursuant to
Rules 144 or 701 will have a substantial burden of proof in establishing that an
exemption from registration is available for such offers or sales, and that such
persons and their respective brokers who participate in such transactions do so
at their own risk. Optionee understands that no assurances can be given that any
such other registration exemption will be available in such event.

        (f) Optionee understands that the certificate evidencing the Securities
may be imprinted, if required by the state of California, with a legend which
prohibits the transfer of the Securities without the consent of the Commissioner
of Corporations of

<PAGE>

        California. At the time of exercise, Optionee will be furnished with a
copy of the applicable Commissioner's Rules with respect to such restriction, if
any.

                                        Signature of Optionee:

                                        ________________________________________

                                        Date: ________________, 20__

<PAGE>

                                PURPLE RAY, INC.

                                 2000 STOCK PLAN

                         ATTACHMENT 1 TO EXERCISE NOTICE

              STOCK POWER AND ASSIGNMENT SEPARATE FROM CERTIFICATE

FOR VALUE RECEIVED and pursuant to that certain Exercise Notice and Restricted
Stock Agreement dated as of __________, 20__, the undersigned hereby sells,
assigns and transfers unto ___________________________________________,
_______________ shares of the Common Stock of Purple Ray, Inc., a California
corporation, standing in the undersigned's name on the books of said corporation
represented by Certificate No. __________ delivered herewith, and does hereby
irrevocably constitute the Secretary of said corporation as attorney-in-fact,
with full power of substitution, to transfer said stock on the books of said
corporation.

Dated:  __________, 20__

                                            ____________________________________
                                                         (Signature)

                                            ____________________________________
                                                     (Please Print Name)

                                            ____________________________________
                                                (Spouse's Signature, if any)

                                            ____________________________________
                                                     (Please Print Name)

<PAGE>

                                PURPLE RAY, INC.

                                 2000 STOCK PLAN

                         ATTACHMENT 2 TO EXERCISE NOTICE

                            JOINT ESCROW INSTRUCTIONS

___________, 20__

Secretary
Purple Ray, Inc.

Dear Sir:

               As Escrow Agent for both Purple Ray, Inc., a California
corporation ("Corporation"), and the undersigned purchaser of stock of the
Corporation ("Purchaser"), you are hereby authorized and directed to hold the
documents delivered to you pursuant to the terms of that certain Restricted
Stock Agreement ("Agreement"), dated as of __________, 20__, to which a copy of
these Joint Escrow Instructions is attached, in accordance with the following
instructions:

               1. In the event the Corporation and/or any assignee of the
Corporation (referred to collectively for convenience herein as the
"Corporation") exercises the Repurchase Option set forth in the Agreement, the
Corporation shall give to Purchaser and you a written notice specifying the
number of shares of stock to be purchased, the purchase price, and the time for
a closing hereunder at the principal office of the Corporation. Purchaser and
the Corporation hereby irrevocably authorize and direct you to close the
transaction contemplated by such notice in accordance with the terms of said
notice.

               2. At the closing, you are directed (a) to date the stock
assignments necessary for the transfer in question, (b) to fill in the number of
shares being transferred, and (c) to deliver same, together with the certificate
evidencing the shares of stock to be transferred, to the Corporation against the
simultaneous delivery to you of the purchase price (by check or by cancellation
of any debt owed by Purchaser to the Corporation) for the number of shares of
stock being purchased pursuant to the exercise of the Repurchase Option.

               3. Purchaser irrevocably authorizes the Corporation to deposit
with you any certificates evidencing shares of stock to be held by you hereunder
and any additions and substitutions to said shares as defined in the Agreement.
Purchaser does hereby irrevocably constitute and appoint you as his
attorney-in-fact and agent for the term of this escrow to execute with respect
to such securities all documents necessary or appropriate to make such
securities negotiable and to complete any transaction herein contemplated,
including but not limited to the filing with the Department of Corporations of
the State of California of an Application for Consent to Transfer Securities
Subject to Legend or Escrow Condition Pursuant to Section 25151 of the
California Corporate Securities Law of 1968. Subject to the provisions of this
paragraph 3, Purchaser shall exercise all rights and privileges of a stockholder
of the Corporation while the stock is held by you.

               4. Upon written request of the Purchaser after each successive
one-year period from the date of the Agreement, unless the Repurchase Option has
been exercised, you will deliver to Purchaser a certificate or certificates
representing so many shares of stock as are not then subject to the Repurchase
Option. Ninety days after cessation of Purchaser's service to the Company, you
will deliver to Purchaser a certificate or certificates representing the
aggregate

                                       1
<PAGE>

number of shares sold and issued pursuant to the Agreement and not purchased by
the Corporation or its assignees pursuant to exercise of the Repurchase Option.

               Notwithstanding the foregoing, none of the certificates
representing the shares of stock deposited under these escrow instructions shall
be released to the Purchaser if the Purchaser's Note given in payment for such
shares has not been paid in full. So long as any Note is outstanding, the shares
shall be held by you as collateral for the obligation under the Note. Subject to
the provisions of this paragraph 4, upon payment of the Note in full the
certificates representing the shares may be released and delivered to the
Purchaser. In the event Purchaser defaults in payment of the Note when due, you
shall, upon written request of the Corporation, deliver the certificate
evidencing the shares of stock and the stock assignments to the Corporation to
enable the Corporation to exercise its rights as a secured party under the
Commercial Code of the State of California.

               5. If at the time of termination of this escrow you should have
in your possession any documents, securities, or other property belonging to
Purchaser, you shall deliver all of same to Purchaser and shall be discharged of
all further obligations hereunder.

               6. Your duties hereunder may be altered, amended, modified or
revoked only by a writing signed by all of the parties hereto.

               7. You shall be obligated only for the performance of such duties
as are specifically set forth herein and may rely and shall be protected in
relying or refraining from acting on any instrument reasonably believed by you
to be genuine and to have been signed or presented by the proper party or
parties. You shall not be personally liable for any act you may do or omit to do
hereunder as Escrow Agent or as attorney-in-fact for Purchaser while acting in
good faith and in the exercise of your own good judgment, and any act done or
omitted by you pursuant to the advice of your own attorneys shall be conclusive
evidence of such good faith.

               8. You are hereby expressly authorized to disregard any and all
warnings given by any of the parties hereto or by any other person or
corporation, excepting only orders or process of courts of law, and are hereby
expressly authorized to comply with and obey orders, judgments or decrees of any
court. In case you obey or comply with any such order, judgment or decree, you
shall not be liable to any of the parties hereto or to any other person, firm or
corporation by reason of such compliance, notwithstanding any such order,
judgment or decree being subsequently reversed, modified, annulled, set aside,
vacated or found to have been entered without jurisdiction.

               9. You shall not be liable in any respect on account of the
identity, authorities or rights of the parties executing or delivering or
purporting to execute or deliver the Agreement or any documents or papers
deposited or called for hereunder.

               10. You shall not be liable for the outlawing of any rights under
the Statute of Limitations with respect to these Joint Escrow Instructions or
any documents deposited with you.

               11. You shall be entitled to employ such legal counsel and other
experts as you may deem necessary properly to advise you in connection with your
obligations hereunder, may rely upon the advice of such counsel, and may pay
such counsel reasonable compensation therefor.

               12. Your responsibilities as Escrow Agent hereunder shall
terminate if you shall cease to be Secretary of the Corporation or if you shall
resign by written notice to each party. In the event of any such termination,
the Corporation shall appoint a successor Escrow Agent.

                                       2
<PAGE>

               13. If you reasonably require other or further instruments in
connection with these Joint Escrow Instructions or obligations in respect
hereto, the necessary parties hereto shall join in furnishing such instruments.

               14. It is understood and agreed that should any dispute arise
with respect to the delivery and/or ownership or right of possession of the
securities held by you hereunder, you are authorized and directed to retain in
your possession without liability to anyone all or any part of said securities
until such disputes shall have been settled either by mutual written agreement
of the parties concerned or by a final order, decree or judgment of a court of
competent jurisdiction after the time for appeal has expired and no appeal has
been perfected, but you shall be under no duty whatsoever to institute or defend
any such proceedings.

               15. Any notice required or permitted hereunder shall be given in
writing and shall be deemed effectively given upon personal delivery or upon
deposit in the United States Post Office, by registered or certified mail with
postage and fees prepaid, addressed to each of the other parties thereunto
entitled at the following addresses, or at such other addresses as a party may
designate by ten (10) days' advance written notice to each of the other parties
hereto.

                CORPORATION:          PURPLE RAY, INC.

                PURCHASER:            ______________________________
                                      ______________________________
                                      ______________________________
                                      ______________________________

                ESCROW AGENT:         Secretary
                                      PURPLE RAY, INC.

                                      ______________________________

               16. By signing these Joint Escrow Instructions, you become a
party hereto only for the purpose of said Joint Escrow Instructions; you do not
become a party to the Agreement.

               17. This instrument shall be binding upon and inure to the
benefit of the parties hereto, and their respective successors and permitted
assigns.

                                        Very truly yours,

                                        PURPLE RAY, INC.
                                        a California corporation

                                            By _________________________________

                                            Title ______________________________

                                            PURCHASER

                                            ____________________________________
                                            ESCROW AGENT

                                            ____________________________________
                                                          Secretary

                                       3
<PAGE>

                                PURPLE RAY, INC.
                                 2000 STOCK PLAN

                         ATTACHMENT 3 TO EXERCISE NOTICE

ALTERNATIVE MINIMUM TAX ELECTION UNDER SECTION 83(b) OF THE INTERNAL REVENUE
CODE OF 1986

               The undersigned Taxpayer hereby elects, pursuant to the
provisions of Sections 55-56 and 83(b) of the Internal Revenue Code of 1986, as
amended, to include in alternative minimum taxable income for the Taxpayer's
current taxable year, as compensation for services, the excess, if any, of the
fair market value of the property described below at the time of transfer over
the amount paid for such property.

1.      Taxpayer's Name: _______________________________________________________

        Taxpayer's Address: ____________________________________________________

                            ____________________________________________________

        Social Security Number:_________________________________________________

2.      The property with respect to which the election is made is described as
        follows: ___________ shares of Common Stock of Purple Ray, Inc., a
        California corporation (the "Company"), which is Taxpayer's employer or
        the corporation for whom the Taxpayer has performed services.

3.      The date on which the shares were transferred was ___________, 20__, and
        this election is made for calendar year 20__.

4.      The shares are subject to the following restrictions:

        The Company may repurchase all or a portion of the shares at the
        Taxpayer's original purchase price under certain conditions at the time
        of Taxpayer's termination of employment or services.

5.      The fair market value of the shares (without regard to restrictions
        other than restrictions which by their terms will never lapse) was
        $_________ per share at the time of transfer.

6.      The amount paid for such shares was $________ per share.

7.      The Taxpayer has submitted a copy of this statement to the Company as
        the Taxpayer's employer or the corporation for whom the Taxpayer has
        performed services.

THIS ELECTION MUST BE FILED WITH THE INTERNAL REVENUE SERVICE ("IRS") (AT THE
OFFICE WHERE THE TAXPAYER FILES ANNUAL INCOME TAX RETURNS) WITHIN 30 DAYS AFTER
THE DATE OF TRANSFER OF THE PROPERTY, AND MUST ALSO BE FILED WITH THE TAXPAYER'S
INCOME TAX RETURNS FOR THE CALENDAR YEAR ABOVE STATED. THE ELECTION CANNOT BE
REVOKED WITHOUT THE CONSENT OF THE IRS.

Dated: ______________, 20__                     ________________________________
                                                      Taxpayer's Signature

                                                ________________________________
                                                   Spouse's Signature (if any)

                                       4
<PAGE>

                                PURPLE RAY, INC.
                                 2000 STOCK PLAN

                        ATTACHMENT 3A TO EXERCISE NOTICE

        ELECTION UNDER SECTION 83(b) OF THE INTERNAL REVENUE CODE OF 1986

The undersigned Taxpayer hereby elects, pursuant to the provisions of Section
83(b) of the Internal Revenue Code of 1986, as amended, to include in taxable
income for the Taxpayer's current taxable year, as compensation for services,
the excess, if any, of the fair market value of the property described below at
the time of transfer over the amount paid for such property.

1.      Taxpayer's Name: _______________________________________________________

        Taxpayer's Address: ____________________________________________________

                            ____________________________________________________

        Social Security Number:_________________________________________________

2.      The property with respect to which the election is made is described as
        follows: ___________ shares of Common Stock of PURPLE RAY, INC., a
        California corporation (the "Company"), which is Taxpayer's employer or
        the corporation for whom the Taxpayer has performed services.

3.      The date on which the shares were transferred was ___________, 20__, and
        this election is made for calendar year 20__.

4.      The shares are subject to the following restrictions:

        The Company may repurchase all or a portion of the shares at the
        Taxpayer's original purchase price under certain conditions at the time
        of Taxpayer's termination of employment or services.

5.      The fair market value of the shares (without regard to restrictions
        other than restrictions which by their terms will never lapse) was
        $_________ per share at the time of transfer.

6.      The amount paid for such shares was $________ per share.

7.      The Taxpayer has submitted a copy of this statement to the Company as
        the Taxpayer's employer or the corporation for whom the Taxpayer has
        performed services.

THIS ELECTION MUST BE FILED WITH THE INTERNAL REVENUE SERVICE ("IRS") (AT THE
OFFICE WHERE THE TAXPAYER FILES ANNUAL INCOME TAX RETURNS) WITHIN 30 DAYS AFTER
THE DATE OF TRANSFER OF THE PROPERTY, AND MUST ALSO BE FILED WITH THE TAXPAYER'S
INCOME TAX RETURNS FOR THE CALENDAR YEAR ABOVE STATED. THE ELECTION CANNOT BE
REVOKED WITHOUT THE CONSENT OF THE IRS.

Dated: ______________, 20__                     ________________________________
                                                      Taxpayer's Signature

                                                ________________________________
                                                   Spouse's Signature (if any)<PAGE>
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                                                   EXHIBIT 10.33

                           LABCHIP SOLUTIONS AGREEMENT

        This LABCHIP SOLUTIONS AGREEMENT ("Agreement"), dated as of September
21, 2001 (the "Effective Date"), is entered into by and between AMPHORA
DISCOVERY CORP., a Delaware corporation ("Amphora"), and CALIPER TECHNOLOGIES
CORP., a Delaware corporation ("Caliper"). Any capitalized terms used herein but
not defined shall have the meaning ascribed to them in the Intellectual Property
Agreement.

                                    RECITALS

        WHEREAS, Caliper has developed proprietary microfluidics and
miniaturization technology applicable to pharmaceutical candidate Screening
techniques; and

        WHEREAS, Amphora is in the business of screening agents and compounds
using Caliper's technology and commercializing the data for use by third
parties; and

        WHEREAS, Caliper and Amphora have entered into an Intellectual Property
Agreement of even date herewith which contains certain exclusivity, licensing
and other collaboration provisions; and

        WHEREAS, Caliper and Amphora desire to establish a commercial
relationship for the purchase of Caliper's goods and services by Amphora.

        NOW, THEREFORE, in consideration of the foregoing premises and the
mutual covenants contained in this Agreement, the parties agree as follows:

1.  DEFINITIONS

    1.1.   "AFFILIATE" shall mean, with respect to any Person, any other Person
           controlling, controlled by or under common control with, such Person.
           For purposes of this definition, the term "control" means the
           possession of the power to direct the management or policies of a
           Person through ownership of fifty percent (50%) or more of its voting
           securities entitled to vote in the election of directors (or, in the
           case of a Person that is not a corporation, for the election of the
           corresponding managing authority).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -1-
<PAGE>

    1.2.   "AMPHORA DEVELOPED PRODUCT" shall mean any product or component,
           including software, that is used in or reasonably useful for
           Screening and that is developed or made by or on behalf of Amphora
           pursuant to the license granted in Section 6.1.1, provided that the
           development, manufacture or use of such product by or on behalf of
           Amphora would infringe one or more claims of Patent Rights included
           in the Caliper Intellectual Property absent such license and not
           merely trade secret rights.

    1.3.   "AMPHORA IMPROVEMENTS" shall mean all inventions (whether or not
           patentable), discoveries, methods, compositions and other trade
           secrets and know-how (collectively, "Improvements") that are
           conceived or first reduced to practice by Caliper, solely or jointly
           with others, during the Term and in the course of performing services
           on behalf of Amphora hereunder, except as otherwise mutually agreed
           in writing, or otherwise using Amphora Materials, to the extent they
           are directed to drug discovery uses for biological targets or
           compounds provided by Amphora, or Target Assay Protocols or Screening
           data generated on Amphora's behalf. Amphora Improvements shall
           exclude all LabChip Improvements.

    1.4.   "CALENDAR QUARTER" shall mean a period of three consecutive calendar
           months commencing with any of January, April, July, or October.

    1.5.   "CALIPER INTELLECTUAL PROPERTY" shall have the meaning assigned in
           the Intellectual Property Agreement.

    1.6.   "CHIP" shall mean a microfluidic chip offered for sale or otherwise
           made available by Caliper to any Person, for use in a system which is
           used in, or useful for, Target Assay Protocol development or
           Screening, or otherwise generating data for a Multi-Target Screening
           Database (as defined in the Intellectual Property Agreement).

    1.7.   "CONFIDENTIAL INFORMATION" of a party shall mean all information
           provided by such party to the other party either in connection with
           the discussions and negotiations pertaining to this Agreement or in
           the course of performing this Agreement, whether in writing, orally
           or otherwise, provided that such information is either (i) the type
           of information that is customarily treated as confidential by the
           disclosing party, or (ii) specifically designated as confidential, in
           writing orally or otherwise, at the time of disclosure or reasonably
           promptly thereafter.. Subject to the foregoing, Confidential
           Information may include without limitation, data; knowledge;
           practices; processes; ideas; research plans; chemical compounds;
           engineering designs and drawings; research data; manufacturing
           processes and techniques; scientific, manufacturing, marketing and
           business plans; and financial and personnel matters relating to the
           disclosing party or to its present or future products, sales,
           suppliers, customers, employees, investors or business.
           Notwithstanding the foregoing,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -2-
<PAGE>

           information shall not be deemed Confidential Information for purposes
           of this Agreement if such information:

               (a)    was already known to the receiving party or its
                      Affiliates, other than under an obligation of
                      confidentiality, at the time of disclosure by the
                      disclosing party, as shown by the receiving party's files
                      and records immediately prior to the time of disclosure;

               (b)    was generally available or known to the public or
                      otherwise part of the public domain at the time of its
                      disclosure to the receiving party;

               (c)    became generally available or known to the public or
                      otherwise part of the public domain after its disclosure
                      to the receiving party through no fault of the receiving
                      party;

               (d)    was disclosed to the receiving party or its Affiliates,
                      other than under an obligation of confidentiality, by a
                      third party who had no obligation not to disclose such
                      information to others; or

               (e)    was independently discovered or developed by the receiving
                      party or its Affiliates without the use of Confidential
                      Information belonging to the disclosing party.

    1.8.   "CONTRACT YEAR" shall mean a period of one year commencing on the
           Effective Date or on any anniversary of the Effective Date.

    1.9.   "COST OF GOODS" shall mean the cost of goods sold for the particular
           Product as calculated by Caliper in accordance with GAAP as GAAP is
           applied by Caliper in generating its publicly reported financial
           statements. As used herein, "GAAP" shall mean the then-current
           applicable Generally Accepted Accounting Principles in the United
           States consistently applied as recognized or accepted by the United
           States Securities and Exchange Commission and the Financial
           Accounting Standards Board.

    1.10.  "DATAPOINT" shall mean each time an Instrument System introduces a
           sample into a Chip through a sipper in order to perform a particular
           LabChip Assay. As an example, on a standard Chip, a Datapoint is
           acquired each time a sipper introduces such a sample into the Chip by
           dipping into a well.

    1.11.  "EFFECTIVE DATE" shall have the meaning stated in the introductory
           paragraph of this Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -3-
<PAGE>

    1.12.  "EFFECTIVE FILING DATE" shall mean the earliest effective priority
           filing date to which the Patent Right is entitled in the applicable
           country, as determined on a claim by claim basis, in accordance with
           applicable law. By way of example, it is understood that the
           Effective Filing Date for each claim in a United States patent is the
           earlier of (i) the actual filing date of the United States patent
           application which issued into such patent, (ii) the priority date
           under 35 U.S.C. Section 119 for such claim, or (iii) the priority
           date under 35 U.S.C. Section 120 for such claim.

    1.13.  "FORECAST" shall have the meaning set forth in Section 2.4.1.

    1.14.  "FTE" shall mean one or more Caliper full-time equivalent person(s),
           whether employees, contractors or consultants, engaged in activities
           on Amphora's behalf under this Agreement for the equivalent of one
           full-time employee's time (assuming a 40-hour workweek).

    1.15.  "GENERAL ASSAY PROTOCOL" shall mean the protocol and set of
           biochemical conditions for performing a Screening assay on an
           Instrument System and Chip, which protocol and conditions are
           generally applicable to assays for multiple different biological
           targets.

    1.16.  "INSTRUMENT SYSTEM" shall mean the collection of hardware and
           software for use with Chips in a Screening system offered for sale or
           otherwise made available by Caliper to any Person, which system is
           used in, or useful for, Target Assay Protocol development or
           Screening, or otherwise generating data for a Multi-Target Screening
           Database (as defined in the Intellectual Property Agreement).

    1.17.  "INTELLECTUAL PROPERTY AGREEMENT" shall mean that certain
           Intellectual Property Agreement by and between the parties hereto of
           even date herewith.

    1.18.  "IP" shall mean any and all rights in, to or arising out of any
           Patent Rights, trade secrets, know how or copyright rights.

    1.19.  "LABCHIP ASSAY" shall mean the complete protocol and set of
           biochemical conditions selected by a party for performing a Screening
           assay for a particular biological target on an Instrument System and
           Chip, consisting of the Target Assay Protocol plus the General Assay
           Protocol. LabChip(R) is a registered Caliper trademark but is printed
           without the registration mark in this Agreement for convenience.

    1.20.  "LABCHIP IMPROVEMENTS" shall mean all inventions (whether or not
           patentable), discoveries, methods, compositions and other trade
           secrets and know-how (collectively

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -4-
<PAGE>

           "Improvements") that are conceived or first reduced to practice by
           Amphora, solely or jointly with others, (i) during the Term, (ii)
           based upon or as a result of access to Caliper Intellectual Property
           or products provided under this Agreement or the Related Agreements,
           and (iii) to the extent they are directed to the design, development
           or manufacture of microfluidic chips or chip interfaces. For purposes
           of (iii), "directed to" means that the Improvement does not have a
           material practical application other than with regard to microfluidic
           chips. "Chip interface" means the first tier physical and optical
           interface between a microfluidic chip and associated hardware.
           "LabChip Improvements" specifically include, but are not limited to,
           (a) chip designs and formats, (b) the chip cartridge design, (c) how
           the actuation forces (e.g., pressure, electrical) are applied to the
           chip, (d) physical or chemical methods for measuring temperature in
           channels, (e) Improvements directed to the Library Card System and
           (f) methods of controlling physical conditions for reagents on the
           chip (e.g. control of evaporation and temperature in on-chip
           reservoirs, or control of temperature or pressure in chip channels).
           For purposes of (e), "directed to" means that the Improvement does
           not have a material practical application other than with regard to
           Library Card Systems. "LabChip Improvements" specifically exclude,
           among other things, Target Assay Protocols.

    1.21.  "LIBRARY CARD SYSTEM" shall mean the system for low quantity,
           high-density storage of compounds retrievable with sipper chips, as
           further described in (i) Caliper's internal product lifecycle
           documentation as of the Effective Date, and (ii) pending patent
           applications filed by Caliper.

    1.22.  "LICENSABLE INTELLECTUAL PROPERTY" shall have the meaning assigned in
           the Intellectual Property Agreement.

    1.23.  "MATERIALS" shall have the meaning specified in Section 7.4.

    1.24.  "NEW LAB-ON-A-CHIP PRODUCTS" shall mean any product or component,
           including software, hardware, a microfluidic chip, a reagent, a
           LabChip Assay, that (i) is, or is used in, a chip-based system that
           utilizes Caliper's microfluidic chip technologies, (ii) is used in or
           reasonably useful for Screening and (iii) is not a Product as of the
           Effective Date. New Lab-on-a-Chip Products shall not include anything
           that constitutes a LabChip Improvement or Amphora Improvement.

    1.25.  "PATENT RIGHTS" shall have the meaning assigned in the Intellectual
           Property Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -5-
<PAGE>

    1.26.  "PERSON" shall mean an individual, partnership, firm, corporation,
           limited liability company, joint venture, association, trust, any
           governmental agency or political subdivision thereof, or any other
           legal entity.

    1.27.  "PRODUCTION YEAR" shall mean a period of one year commencing on the
           Validation Date or on any anniversary thereof.

    1.28.  "PRODUCTS" shall mean all Instrument Systems, Chips, and other
           products and components, including hardware, Software and reagents,
           that (i) Caliper offers for sale or otherwise makes available during
           the Term to any Person and (ii) are used in, or useful for, LabChip
           Assay development or Screening, or otherwise generating data for a
           Multi-Target Screening Database (as defined in the Intellectual
           Property Agreement). For avoidance of doubt, Products shall include
           but not be limited to the products set forth in Exhibit B.

    1.29.  "PROJECTED AVAILABILITY DATE" shall have the meaning specified in
           Section 5.3.1.

    1.30.  "PURCHASE TERMS" shall mean the purchase terms and conditions set
           forth in Exhibit A.

    1.31.  "SCHEDULED DELIVERY DATE" shall mean the date on which Amphora has
           requested that a Product shall be shipped to Amphora, subject to the
           ordering lead times set forth in Section 2.4.

    1.32.  "SCREENING" shall have the meaning specified in the Intellectual
           Property Agreement.

    1.33.  "SCREENING DATABASE BUSINESS" shall have the meaning specified in the
           Intellectual Property Agreement.

    1.34.  "SPECIFICATIONS" shall mean the system specifications that accompany
           a Product or that are provided by Caliper in connection with the
           purchase of a Product.

    1.35.  "TARGET ASSAY PROTOCOL" shall mean the protocol and set of
           biochemical conditions for performing a Screening assay on an
           Instrument System and Chip, which protocol and conditions have been
           selected by a party for assaying one particular biological target.
           Target Assay Protocol shall not include any elements of such protocol
           or biochemical conditions that are included in the General Assay
           Protocol.

    1.36.  "TERM" shall have the meaning set forth in Section 12.1.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -6-
<PAGE>

    1.37.  "TWELVE SIPPER SYSTEM" shall mean a system that contains (i) a Chip
           that has twelve sippers, (ii) the instrument and software on which
           such a Chip operates, and (iii) a standard LabChip Assay that can be
           run on the foregoing Chip, Instrument System and software.

    1.38.  "VALIDATION DATE" shall mean the date on which the initial quantities
           of Chips mutually agreed upon by the parties have been delivered to
           Amphora, and the initial shipment of Instrument Systems in a quantity
           to be mutually agreed have been installed by Caliper at Amphora's
           North Carolina offices (or as otherwise mutually agreed), and
           demonstrated by Caliper to function in accordance with the
           Specifications for such Instrument Systems and in performing
           Caliper's standard fluorogenic LabChip Assay. The parties expect such
           testing to be completed by October 31, 2001.

2.  PRODUCTS

    2.1.   PRODUCT SALES. Throughout the Term, Caliper shall make available to
           Amphora all Products that Caliper makes commercially available to any
           customer. Caliper shall make all Products set forth on Exhibit B
           available to Amphora in accordance with the terms and conditions of
           this Agreement (including the Purchase Terms), without additional
           terms or restrictions. Caliper shall make available to Amphora other
           Products in accordance with Caliper's standard terms, provided that
           such Products may be subject to certain additional restrictions,
           limitations, or terms, provided that such restrictions, terms and
           limitations shall be commercially reasonable and shall not materially
           adversely affect Amphora's rights under this Agreement or the
           Intellectual Property Agreement. In addition, during the course of
           this Agreement, Caliper may offer Amphora the opportunity to receive
           products other than Products. For example, Amphora may receive
           products being commercialized through Caliper's research
           collaboration with Agilent. Terms related to such transactions will
           be agreed upon separately or established for all customers by Caliper
           and Agilent, and are not intended to be included under the scope of
           this Agreement except as otherwise set forth herein. Caliper shall
           treat Amphora equally with all other Caliper customers in the
           offering of Products and terms therefor. ANY TERMS OR CONDITIONS OF
           ANY PURCHASE ORDER, ACKNOWLEDGMENT, OR OTHER DOCUMENT ISSUED BY
           EITHER PARTY FOR A PRODUCT SET FORT ON EXHIBIT B WHICH ARE IN
           ADDITION TO OR INCONSISTENT WITH THIS AGREEMENT OR THE INTELLECTUAL
           PROPERTY AGREEMENT SHALL HAVE NO EFFECT AND SUCH TERMS AND CONDITIONS
           ARE HEREBY EXCLUDED, UNLESS SUCH ADDITIONAL TERMS AND CONDITIONS ARE
           SET FORTH IN A WRITING SIGNED BY BOTH PARTIES.

    2.2.   INITIAL SYSTEMS.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -7-
<PAGE>

           2.2.1. INITIAL PURCHASE ORDER. With respect to Products purchased
                 under the first purchase order submitted by Amphora hereunder,
                 Caliper shall resolve any performance issues within five (5)
                 business days of written notice from Amphora.

           2.2.2. PURCHASE COMMITMENT. Subject to the terms and conditions of
                 this Agreement, including the Purchase Terms, and
                 notwithstanding the lead times set forth in Section 2.4,
                 Amphora shall place orders for and take delivery of, at least
                 eleven (11) Instrument Systems prior to December 31, 2001.
                 Caliper shall ship the foregoing Instrument Systems pursuant to
                 a schedule reasonably requested by Amphora. The Instrument
                 Systems ordered concurrently with the execution of this
                 Agreement shall be counted toward the foregoing purchase
                 commitment. Prior to December 31, 2002, Amphora shall purchase,
                 and Caliper shall deliver to Amphora, at least an additional
                 eleven (11) Instrument Systems, subject to the terms and
                 conditions of this Agreement, including the Purchase Terms.
                 Notwithstanding anything to the contrary, Amphora shall have
                 the right to suspend orders and delivery of further Instrument
                 Systems under this Section 2.2 without breach in the event of
                 ongoing, material warranty or installation issues with at least
                 20% of delivered or installed Instrument Systems purchased by
                 Amphora, which issues are not resolved within forty-five (45)
                 days of written notice by Amphora. Upon resolution of the
                 warranty or installation issue, the schedule for delivery of
                 subsequent Instrument Systems will be reasonably adjusted in
                 light of any delay relating to such issue, if such an
                 adjustment is requested by Amphora.

     2.3.  [ * ] PRODUCTS. Notwithstanding Section 2.1, during the Exclusivity
           Period, [ * ] any product reasonably useful for Screening that is
           [ * ] and incorporates any Caliper Intellectual Property, provided
           that Amphora may [ * ] incorporate Caliper Intellectual Property. If
           [ * ] incorporating Caliper Intellectual Property that Caliper [ * ]
           during the Exclusivity Period, then, upon Amphora's request, Caliper
           [ * ] it to Amphora upon commercially reasonable terms.

    2.4.   FORECASTS AND ORDERS.

           2.4.1. FORECASTS. Amphora shall provide to Caliper, within thirty
                 (30) days after the Effective Date and by the fifth day of each
                 subsequent Calendar Quarter during the Term, Amphora's written,
                 good-faith forecast of the quantity of Chips and Instrument
                 Systems that Amphora anticipates it will order in each month
                 during the following twelve-month period (each, a "Forecast"),
                 provided that the number of Chips in the first six (6) months
                 of each Forecast may not be increased by more than 20% over the
                 immediately preceding Forecast for the same period without the
                 written consent of Caliper. If a new Chip or Instrument System
                 is made available hereunder, an initial Forecast shall be
                 provided by Amphora, which initial Forecast shall serve as the
                 first

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -8-
<PAGE>

                 Forecast for such Chip and/or Instrument System under this
                 Section 2.4.1, with deliveries commencing at a date mutually
                 agreed upon by the parties, which Caliper shall not require to
                 be later than when Caliper first makes such Chip or Instrument
                 System available to any third party Caliper shall supply to
                 Amphora the quantities of Chips and Instrument Systems set
                 forth in each Forecast to the extent set forth in Section
                 2.4.2. Notwithstanding anything set forth in this Section 2.4,
                 if a Forecast for two (2) consecutive calendar months exceeds
                 by more than 25% the actual orders placed by Amphora for such
                 months, then Caliper shall be required to supply, in the
                 immediately following calendar month, the lesser of (i) the
                 percentage of Products required under Section 2.4.2 below, or
                 (ii) the percentage of Products required under Section 2.4.2
                 minus the average percentage by which the previous two months'
                 Forecast exceeded actual orders in such months. For example, if
                 the Forecast for two consecutive months exceeded actual orders
                 by 30% and 50% respectively, then Caliper shall only be
                 required to supply 60% of the Products that would otherwise be
                 required for the following month under Section 2.4.2.

           2.4.2. ORDERS. If Amphora provides to Caliper a purchase order for
                 Chips at least three (3) months prior to the Scheduled Delivery
                 Date for such Chips, then Caliper shall supply such Chips by
                 such date, provided that Caliper shall not be required to
                 timely supply that number of Chips which is in excess of 110%
                 of the Forecast in the immediately preceding Calendar Quarter,
                 provided that Caliper shall use commercially reasonable efforts
                 to fill orders for such quantities of Chips from available
                 supplies. If Amphora provides to Caliper a purchase order for
                 Instrument Systems at least six (6) months prior to the
                 Scheduled Delivery Date for such Instrument Systems, then
                 Caliper shall supply such Instrument Systems by such date,
                 provided that Caliper shall not be required to timely deliver
                 that number of Instrument Systems which is in excess of 120% of
                 the Forecast provided to Caliper in the Calendar Quarter prior
                 to the immediately preceding Calendar Quarter, provided that
                 Caliper shall use commercially reasonable efforts to fill
                 orders for such excess quantities of Instrument Systems from
                 available supplies. Caliper shall notify Amphora within fifteen
                 (15) calendar days from receipt of a purchase order of its
                 ability to fill any amounts of such order in excess of the
                 quantities that Caliper is obligated to supply. It is
                 acknowledged and agreed that the parties may mutually agree
                 from time to time to substitute new or improved Chips for
                 existing Chips set forth in Amphora's Forecasts. The
                 appropriate employees from each party shall meet on a monthly
                 basis, or as otherwise mutually agreed, to discuss the
                 Forecasts.

           2.4.3. EARLY DELIVERY. For Chips delivered more than fifteen (15)
                 calendar days in advance of the Scheduled Delivery Date,
                 Amphora shall have the right to return such Chips to Caliper
                 freight collect (with risk of loss remaining on Caliper) or
                 accept such Chips

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -9-
<PAGE>

                 with payment terms based upon the Scheduled Delivery Date and
                 not the date of shipment by Caliper.

3.  SERVICES

    3.1.   GENERAL. During the Term, Amphora shall have the right to request
           that Caliper perform the services set forth herein, and such services
           shall be provided by Caliper to Amphora, and contractors working on
           Amphora's behalf, subject to the terms set forth herein. Services to
           be provided by Caliper shall include, without limitation, (i) LabChip
           Assay development for targets selected by Amphora, (ii) installation,
           maintenance, and support for Product and training and support for
           Amphora personnel developing LabChip Assays or using Products, (iii)
           custom development projects, and (iv) instrument platform extensions.

    3.2.   PROJECT PLAN. Subject to Section 3.4, each year during the Term, or
           as otherwise mutually agreed by the parties, Amphora and Caliper
           shall agree upon the services to be provided by Caliper to Amphora
           during such year or other time period (the "Project Plan"), subject
           to Caliper's determination of commercial and technical feasibility,
           and mutual agreement upon commercially reasonable terms for such
           services. Amphora and Caliper will jointly propose priorities and
           tasks to be accomplished by Caliper to support the Project Plan.
           Caliper will determine the necessary personnel resources and provide
           estimates (in writing, if requested) of the projected time needed to
           perform relevant tasks for, and the technical feasibility of various
           tasks included in, the Project Plan. The parties may amend the
           Project Plan at any time upon mutual agreement.

    3.3.   TYPES OF SERVICE.

           3.3.1. LABCHIP ASSAY DEVELOPMENT. Throughout the Term, LabChip Assays
                 for Amphora's targets will be developed collaboratively by the
                 parties or solely by Amphora, as determined by Amphora. In
                 general, where Caliper is developing a LabChip Assay for
                 Amphora, Amphora will develop the appropriate biochemical
                 and/or cellular reagents for the LabChip Assay and will provide
                 the necessary (as determined by Amphora) quantities of reagents
                 to Caliper. With respect to each Chip for use in a LabChip
                 Assay desired by Amphora, Caliper shall supply such Chip to
                 Amphora in accordance with the terms and conditions in this
                 Agreement, including the ordering and forecasting terms set
                 forth in Section 2.4. Caliper shall use commercially reasonable
                 efforts to make such Chip available to Amphora as soon as
                 possible after Amphora's request.

           3.3.2. TRAINING. As Amphora requests at any time during the Term, one
                 or more Caliper employees shall provide training for Amphora
                 employees in development of LabChip

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -10-
<PAGE>

                 Assays and use of Products, with the intended result of making
                 Amphora independent in its use of the Products and in LabChip
                 Assay development. The parties will attempt to schedule such
                 training at mutually convenient times, provided that Caliper
                 shall use commercially reasonable efforts to meet the timing
                 requested by Amphora. Caliper shall also use commercially
                 reasonable efforts to provide the training at the locations
                 requested by Amphora, including a number of visits to Amphora's
                 facilities in North Carolina to be mutually agreed.

           3.3.3. INSTALLATION. It is acknowledged and agreed that, if the
                 parties have not previously agreed upon an installation date
                 for an Instrument System or component thereof, then within
                 thirty (30) calendar days after Amphora's request for
                 installation, Caliper shall install such Instrument System at
                 the location specified by Amphora. There shall be no charge by
                 Caliper for such installation of each such Instrument System at
                 one initial location, it being understood that the fees for
                 such services are included in Amphora's purchase price for such
                 Instrument System. The parties shall mutually agree upon the
                 installation, testing and acceptance criteria and processes for
                 Instrument Systems.

           3.3.4. MAINTENANCE AND SUPPORT. Caliper shall provide software and
                 equipment upgrades at Caliper's option, and technical telephone
                 support of Products, pursuant to the Purchase Terms set forth
                 in Exhibit A at no charge, it being understood that the fees
                 for such upgrades and support are included in Amphora's
                 purchase price for the applicable Product. Additional upgrades,
                 maintenance and support services shall be available at an
                 additional charge.

    3.4.   FIRST YEAR FTES. Subject to the terms and conditions of this
           Agreement, during the first Contract Year, Caliper shall provide to
           Amphora, and Amphora shall request, the assistance and support of
           four (4) FTEs. Amphora shall have the right to use FTEs under this
           Section 3.4 for the performance of any services set forth herein,
           including the services set forth in this Article 3, subject to the
           terms of a Project Plan. Caliper and Amphora shall agree upon a
           Project Plan for such 4 FTEs. The parties may mutually agree in
           writing to adjust the foregoing FTE commitment.

    3.5.   QUALIFICATIONS. All services performed hereunder will be performed in
           a high quality, professional, and workmanlike manner consistent with
           industry practices and standards applicable to services of the type
           being provided. Caliper will use commercially reasonable efforts at
           all times to assign only individuals with the skills, experience,
           training and qualifications reasonably sufficient to perform services
           in accordance with this Agreement. Amphora shall have the right to
           require Caliper to replace, within sixty (60) days following
           Amphora's written request, any individual performing services who
           Amphora determines does not meet the criteria set forth above. If
           Caliper fails to comply with its obligations this

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -11-
<PAGE>

           Section 3.5, then at Amphora's request and at no cost or expense to
           Amphora, Caliper shall promptly re-perform the relevant services.
           Caliper shall use commercially reasonable efforts in order to
           minimize materially disruptive changes in the Caliper personnel that
           provide Amphora support during a project.

    3.6.   AGREEMENTS WITH EMPLOYEES AND CONSULTANTS. Caliper shall have and
           maintain an agreement with each employee, consultant, and other
           individual performing services for Amphora under this Agreement such
           that, as between Caliper and such individual, all technology and IP
           invented or developed by such individual in the course of performing
           the services is assigned to and owned solely by Caliper. As between
           Caliper and Amphora, ownership shall be determined in accordance with
           the terms and conditions of this Agreement or a Related Agreement
           unless otherwise agreed in a writing signed by both parties.

    3.7.   FACILITY RULES. All individuals provided by Caliper to perform
           services, while on Amphora's premises, shall comply with all
           applicable rules and regulations of Amphora. No such individual shall
           stop, delay or interfere with Amphora's day-to-day operations without
           the prior written consent of Amphora. Caliper shall be solely
           responsible for compliance with the laws, rules, and regulations of
           any government entity with respect to all such individuals, including
           employment of labor, hours of labor, payment of wages, payment of
           taxes, unemployment, social security and other payroll taxes, and
           obtaining applicable contributions from such individuals when so
           required by law.

    3.8.   THIRD PARTY TECHNOLOGY. Caliper shall not use any IP or technology
           owned by a third party in connection with any services hereunder, or
           disclose any such third party IP or technology to Amphora, unless
           Caliper obtains Amphora's prior written consent and provides Amphora
           with all information reasonably requested by Amphora regarding such
           IP and technology, in each case, if Caliper's use of such third party
           technology in connection with the provision of services to Amphora,
           or Amphora's exploitation of the results of Caliper's services, would
           violate any agreement with or proprietary right of the third party.

    3.9.   DEVELOPMENT RECORDS. Caliper shall make commercially reasonable
           efforts to maintain reasonable records relating to services provided
           under this Agreement.

    3.10.  REPORTING. Caliper shall deliver written reports to Amphora within
           the first ten (10) days of each Calendar Quarter describing the
           actual time applied by Caliper's employees and designees to Amphora
           support tasks in the preceding Calendar Quarter. Such reports shall
           include a reasonable description of the project, the name of each
           individual performing the work, and the time spent by such individual
           to perform the project on a daily basis.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -12-
<PAGE>

4.  PRICING AND PAYMENTS

    4.1.   INSTRUMENT SYSTEM PRICING. Instrument Systems identified on Exhibit C
           (and materially similar Instrument Systems with minor modifications
           or improvements) (collectively, "Current Instrument Systems") and all
           Instrument Systems other than Current Instrument Systems ("Future
           Instrument Systems") purchased during the first two Contract Years
           shall be offered to Amphora at the discounts set forth in Exhibit C.
           The discount rate for Class I Products shall be based upon the total
           aggregate number of Class I Products purchased in the then current
           Contract Year. The discount rate for Class II Products shall be based
           upon the total aggregate number of Class II Products purchased in the
           then current Contract Year. Future Instrument System purchases in
           each Contract Year shall be aggregated with Amphora's total purchases
           of Current Instrument Systems during such Contract Year within each
           Instrument System class set forth on Exhibit C for the purpose of
           determining Amphora's discount rate for such Future Instrument
           Systems. For purposes of Exhibit C, "Class I" Instrument Systems are
           Current Instrument Systems and Future Instrument Systems for
           Screening that have environmental controls and plate handling
           capability, and "Class II" Instrument Systems are Current Instrument
           Systems and Future Instrument Systems that do not include
           environmental controls and plate handling capability.

    4.2.   CHIP AND DATAPOINT PRICING. Until the end of the second Production
           Year, the pricing for each Chip and Datapoint derived from a Chip
           shall be as set forth in this Section 4.2.

           4.2.1. CHIPS. Subject to the terms and conditions of this Agreement,
                 Caliper will sell Chips to Amphora at the lesser of (i) the
                 then-current list price for the volumes purchased by Amphora
                 (the current list price for a 4-sipper Chip is $250), or (ii)
                 Caliper's Cost of Goods plus a percentage mark-up not to exceed
                 50% of the Cost of Goods for the applicable Chip.

           4.2.2. DATAPOINTS.

                 4.2.2.1. FIRST PRODUCTION YEAR. Subject to the terms and
                        conditions of this Agreement, Amphora shall pay to
                        Caliper a one-time fixed price of $2,000,000 for all
                        Datapoints generated prior to the end of the first
                        Production Year, regardless of the number of Datapoints
                        actually generated.

                 4.2.2.2. SECOND PRODUCTION YEAR. Subject to the terms and
                        conditions of this Agreement, Amphora shall pay to
                        Caliper a one-time minimum price of US$4,000,000, and a
                        maximum total aggregate price of $6,000,000, for all
                        Datapoints produced during the second Production Year.
                        If Amphora produces [ * ] Datapoints during the second
                        Production Year, then Amphora shall pay Caliper [ * ]
                        produced by

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -13-
<PAGE>

                        Amphora during the second Production Year (such
                        additional price to be paid monthly thereafter in
                        accordance with Section 4.5.3), up to a maximum total
                        price of US$6,000,000 for all Datapoints generated in
                        the second Production Year.

                 4.2.2.3. VALID DATAPOINTS. If Amphora submits a service or
                        warranty claim for a defective Chip or Instrument
                        System, then the Datapoints generated by such Chip or
                        Instrument System during the period in which Amphora
                        claims that such Chip or Instrument System was defective
                        shall not count towards the total number of Datapoints
                        generated by Amphora for purposes of invoicing Amphora
                        for Datapoint fees under Section 4.2.2.2 above, provided
                        that (i) Amphora shall have in place sufficient quality
                        control procedures to, and shall in the event of a
                        warranty claim, cease use of, the allegedly defective
                        Chip or Instrument System within one (1) day of Amphora
                        becoming aware of the defect; (ii) Amphora shall report
                        such defective Product and, in the event of a defective
                        Chip, return the Chip to Caliper, within five (5)
                        calendar days of Amphora becoming aware of the defect,
                        and (iii) the claim was subsequently verified or
                        accepted by Caliper, such review by Caliper to occur
                        within thirty (30) days after the claim is submitted by
                        Amphora. The parties shall cooperate to establish
                        further procedures to administer this Section 4.2.2.3.

                 4.2.2.4. FAILURE OF CHIP SUPPLY. Notwithstanding Sections
                        4.2.2.1 and 4.2.2.2, if, in any Calendar Quarter during
                        the first two Production Years, Caliper fails to supply
                        to Amphora by the Scheduled Delivery Date at least 80%
                        of the Chips that Caliper is required to supply pursuant
                        to Section 2.4, then a percentage of the quarterly
                        Datapoint fees that were paid by Amphora at the
                        beginning of such Calendar Quarter shall be reimbursed
                        by Caliper to Amphora as a credit or refund in
                        accordance with Section 4.2.2.6 below. The percentage of
                        such Datapoint fees to be reimbursed shall equal the
                        difference between 100% and the actual percentage of
                        such Chips delivered by Caliper to Amphora by the
                        Scheduled Delivery Date during such Calendar Quarter.

                 4.2.2.5. CHIP WARRANTY ISSUES. Notwithstanding Sections 4.2.2.1
                        and 4.2.2.2, if, in any Calendar Quarter during the
                        first two Production Years, more than 20% of Chips
                        delivered in any Calendar Quarter are returned by
                        Amphora due to a warranty claim, and Caliper's warranty
                        or service organization agrees to provide any
                        accommodation to Amphora in view of such warranty claim
                        (applying the same standards Caliper applies to warranty
                        claims from its other customers), then a percentage of
                        the quarterly Datapoint fees that were paid by Amphora
                        at the beginning of such Calendar Quarter shall be
                        reimbursed by Caliper to Amphora as a credit or refund
                        in accordance with Section 4.2.2.6 below. The percentage
                        of

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -14-
<PAGE>

                        Datapoint fees to be reimbursed shall equal the
                        difference between 100% and the percentage of Chips
                        delivered to Amphora during such Calendar Quarter that
                        were not the subject of an acknowledged warranty claim
                        as set forth above.

                 4.2.2.6. REIMBURSEMENT PROCEDURE. Each reimbursement accruing
                        in a Calendar Quarter pursuant to this Section 4.2.2
                        shall be provided by Caliper to Amphora as a credit
                        against Datapoint fees due at the beginning of the
                        immediately following Calendar Quarter; provided that if
                        the applicable failure or delay occurs during the last
                        Calendar Quarter for which a quarterly payment is made
                        under Sections 4.2.2.1 and 4.2.2.2, then reimbursement
                        shall be provided as refund paid by Caliper to Amphora
                        within thirty (30) days after the end of such Calendar
                        Quarter. Any reimbursements or reductions of quarterly
                        Datapoint fees pursuant to this Section 4.2.2 shall be
                        cumulative, provided that reimbursements by Caliper
                        shall not exceed the total amount of Datapoint fees due
                        to Caliper in any Calendar Quarter.

    4.3.   SERVICES PRICING. From the Effective Date until the end of the first
           Production Year, services provided hereunder shall be invoiced at a
           rate of [ * ] (excluding travel expenses for which Amphora is
           responsible as set forth below). Thereafter, such services shall be
           provided by Caliper at rate that is no greater than Caliper's
           then-current list price for comparable services. Amphora will
           reimburse Caliper for Caliper's out of pocket costs of airfare, hotel
           accommodations, and meals reasonably necessary in connection with the
           applicable service pursuant to a reimbursement policy mutually agreed
           by the parties.

    4.4.   [ * ]. From the beginning of [ * ] until the end of the Term, when
           Amphora enters into negotiations with Caliper regarding the pricing
           and other purchase terms of Datapoints and/or Products ("[ * ]
           Products"), [ * ].

    4.5.   PAYMENT TERMS.

           4.5.1. GENERAL. All amounts set forth in this Agreement are in U.S.
                 dollars. Caliper shall invoice Amphora on the date of shipping
                 of a Product. Amphora shall pay all invoices within thirty (30)
                 calendar days of receipt. Except as expressly set forth herein,
                 Caliper shall bear all direct and other costs associated with
                 its personnel performing services. Except as set forth in the
                 Purchase Terms, each party shall be solely responsible for and
                 shall pay all taxes based on amounts it receives in the
                 connection with this Agreement and will fully indemnify the
                 other party for any failure to pay such taxes. If a party does
                 not pay an amount payable to the other party under this
                 Agreement on or prior to the due date, late fees shall accrue
                 and become immediately due and payable on the outstanding
                 unpaid balance at a rate of the lower of one and one-half
                 percent (1.5%) per month or the highest amount permitted by
                 law. Caliper shall have the right, at its

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -15-
<PAGE>

                 option, to discontinue the provision of services hereunder upon
                 ten (10) days notice (with a right to cure) if Amphora has not
                 paid an undisputed invoice within ninety (90) days of receipt
                 of proper invoice.

           4.5.2. SERVICES. Caliper shall invoice Amphora quarterly in advance
                 for services provided pursuant to a Project Plan. During the
                 first Contract Year, such invoices shall be for a minimum of
                 [ * ] provided that Caliper has made such FTEs reasonably
                 available to Amphora. The fees for each quarter in subsequent
                 years shall be based on the number of hours of support
                 scheduled to be provided for such quarter pursuant to a Project
                 Plan. Requests at any time for Caliper support for a program in
                 excess of the amounts set forth in the Project Plan or
                 otherwise previously agreed upon shall be subject to mutual
                 agreement. The parties shall reconcile any discrepancy between
                 funding and actual Caliper time provided for each quarter
                 within thirty (30) days after the final report for the
                 preceding Calendar Quarter has been delivered to Amphora.
                 Amphora shall not be responsible for any FTE costs or other
                 fees for service except to the extent that the cost and fees
                 have been approved in advance in a further writing signed by
                 Amphora, (not including Amphora's obligation with respect to
                 the four (4) FTEs for the first Contract Year as set forth in
                 Section 3.4 above) and Caliper shall not be obligated to
                 perform any activities unless such activities have been
                 approved by Amphora in writing.

           4.5.3. VARIABLE DATAPOINT FEES. The Datapoint fees set forth in
                 Sections 4.2.2.1 and 4.2.2.2 shall be payable on a quarterly
                 basis in four equal installments, subject to applicable
                 reductions as set forth in Section 4.2.2 after the beginning of
                 each of the four Calendar Quarters consecutively following the
                 beginning of the first or second Production Year, as
                 applicable. In the event that Amphora generates Datapoints in
                 excess of [ * ] during the second Production Year, the parties
                 shall agree on the process for reporting and payment for such
                 Datapoints, including the timing of such payments.

           4.5.4. RECORDS AND INSPECTION. In addition to the development records
                 required under Section 3.9, each party shall keep complete,
                 true and accurate books of account and records sufficient to
                 determine and establish the applicable party's compliance with
                 its obligations under Sections 2.1, 3.6, 4.2.1, 4.2.2 and 4.4.
                 Such books and records shall be kept reasonably accessible for
                 three (3) years following the end of the Calendar Quarter to
                 which they pertain. All such records maintained by a party
                 shall be made available for inspection by the other party
                 throughout such three (3) year period by an independent third
                 party auditor selected by mutual agreement of the parties. Such
                 inspections may be made at any time during a party's normal
                 business hours upon five (5) days advance notice. The
                 requesting party shall bear the costs and expenses of
                 inspections conducted under this Section 4.5.4, unless a
                 material non-compliance with this Agreement is identified,
                 whereupon all costs of the audit paid to third parties will

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -16-
<PAGE>

                 be paid by the audited party. In the event that an audit
                 demonstrates that payment from one party to another party is
                 required hereunder, the paying party shall make such payment
                 within thirty (30) days after completion of the audit, together
                 with interest on such overpayment at the rate specified in
                 Section 4.5.1.

5.  COLLABORATION AND DEVELOPMENT.

    5.1.   CUSTOM DEVELOPMENT. If Amphora would like to have Caliper develop new
           products or modify existing Caliper products to customize them to
           Amphora's specifications, then Caliper shall negotiate with Amphora
           in good faith regarding an agreement under which Caliper is obligated
           to provide such custom development services. Custom development
           projects may be conducted pursuant to the following general terms
           (the specific terms of which shall be negotiated later by the
           parties):

                             (a) Amphora may fund all Caliper FTEs at a rate to
                                 be mutually agreed.

                             (b) Amphora controls the project's objectives and
                                 budget, subject to Caliper's discretion as to
                                 technical feasibility and potential
                                 infringement of third party IP. The parties
                                 mutually agree on how to achieve the
                                 objectives, reasonable timelines and
                                 milestones, roles and responsibilities, etc.
                                 The parties may also agree on incentives to
                                 spur the development process.

                             (c) Caliper may have rights to commercialize
                                 resulting products. However, Amphora may have a
                                 period of exclusivity or other competitive
                                 advantage with respect to use of such products
                                 in a Screening Database Business.

                             (d) Depending on the scale of the project and other
                                 factors, the parties may negotiate some form of
                                 royalty.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -17-
<PAGE>

    5.2    ACCELERATED DEVELOPMENT. Amphora and Caliper may mutually agree to
           accelerate a product in the Caliper product development lifecycle,
           and the following general terms may apply: (i) Caliper may control
           the project's objectives, (ii) Amphora may fund less than 100% of
           Caliper's FTEs, and (iii) an exclusivity period may or may not apply.
           The parties have agreed that, subject to agreement on terms, Amphora
           may accelerate the development of the Twelve Sipper System and the
           Library Card System under this Section 5.2 (not as a custom project
           under Section 5.1) once such systems have entered the Laboratory
           Phase pursuant to terms mutually agreed by the parties. If Amphora
           would like to have Caliper accelerate development of any system or
           product, then Caliper shall negotiate with Amphora in good faith
           regarding an agreement under which Caliper is obligated to provide
           such services.

    5.3    TWELVE SIPPER AND LIBRARY CARD SYSTEMS.

           5.3.1 AVAILABILITY. Caliper currently expects that the Twelve Sipper
                 System will enter the laboratory prototype phase of its product
                 lifecycle (the "Laboratory Phase") by [ * ] and currently
                 expects that the Library Card System will enter the Laboratory
                 Phase by [ * ] (each, the "Projected Availability Date").
                 Caliper shall keep Amphora fully informed regarding Caliper's
                 progress toward each of the Projected Availability Dates and
                 shall notify Amphora promptly in writing in the event of any
                 potential delay in either Projected Availability Date,
                 describing in such notice Caliper's best estimate of the
                 revised Projected Availability Date.

           5.3.2 INCENTIVE AND LATE FEES. If the Twelve Sipper System enters the
                 Laboratory Phase by [ * ] then Amphora shall pay to Caliper a
                 one-time incentive fee of [ * ]. If the Twelve Sipper System
                 enters the Laboratory Phase on or after [ * ] then Caliper
                 shall pay to Amphora a one-time late fee of [ * ]. If the
                 Library Card System enters the Laboratory Phase by [ * ] then
                 Amphora shall pay to Caliper a one-time incentive fee of [ * ].
                 If the Library Card System enters the Laboratory Phase on or
                 after [ * ] then Caliper shall pay to Amphora a one-time late
                 fee of [ * ]. Any incentive payments paid by Amphora under this
                 Section shall not be counted towards Amphora's Minimums as set
                 forth in Section 3.4 of the Intellectual Property Agreement.

6.  LICENSE FOR AMPHORA DEVELOPED PRODUCTS

    6.1.   LICENSE GRANT.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -18-
<PAGE>

           6.1.1. LICENSE FOR SCREENING DATABASE BUSINESS. Subject to the terms
                 and conditions of this Agreement, Caliper hereby grants to
                 Amphora a worldwide, non-exclusive, fully paid up, royalty
                 free, right and license, under the Licensable Intellectual
                 Property having an Effective Filing Date or generated prior to
                 the third anniversary of the Effective Date to develop, make
                 and use products for Screening, excluding all microfluidic
                 chips and chip cartridges and any products which are
                 substantially the same as a Product, for use for any purpose
                 and any application (including use to practice any method or
                 process) related or reasonably ancillary to (i) its Screening
                 Database Business, or (ii) providing contract Screening
                 services. Notwithstanding the foregoing, Amphora agrees that it
                 will not exercise the license in this Section 6.1 to use a
                 product for Screening to provide contract Screening services
                 without obtaining Caliper's prior written consent to such
                 development, which consent shall not be unreasonably withheld.
                 The foregoing license grant is subject to all the terms and
                 conditions set forth in Sections 2.3 through 2.7 of the
                 Intellectual Property Agreement regarding license rights to
                 Screening Products, as well as the terms and conditions set
                 forth below in this Article 6. The rights set forth in this
                 Article 6 may not be sublicensed, shared or transferred in any
                 manner without the prior written consent of Caliper, except as
                 otherwise provided in Section 6.8 below and in Section 14.5 .
                 If Caliper releases a Product after Amphora has already begun
                 development of an Amphora Developed Product that is
                 substantially the same as such Product, then the license set
                 forth in this Section 6.1 shall apply to such Amphora Developed
                 Product.

           6.1.2. LICENSE TO SELL TARGET ASSAY PROTOCOLS. Subject to the terms
                 and conditions of this Agreement, Caliper hereby grants to
                 Amphora a worldwide, non-exclusive, fully paid up, royalty
                 free, right and license, under the Licensable Intellectual
                 Property having an Effective Filing Date or generated prior to
                 the third anniversary of the Effective Date to sell and
                 disclose Target Assay Protocols for use with Instrument Systems
                 and Chips offered for sale by Caliper or any Caliper Partner.

    6.2.   MODIFICATIONS OF PRODUCTS. The license set forth in Section 6.1 above
           includes the right to modify in any way any hardware or software
           included in a Product purchased by Amphora from Caliper. However, if
           any such modification is made, all warranty and other service
           commitments made by Caliper in connection with the sale of the
           particular Product unit that has been modified will be voided, and
           Caliper will not be obligated to support or provide upgrades for such
           modified Product unit unless the parties have otherwise agreed in
           writing. Upon request by Amphora, Caliper will provide source code
           for any software (including firmware) installed on or provided with a
           Product purchased by Amphora. If Amphora desires any further
           assistance from Caliper to modify such software or develop software
           for an Amphora Developed Product, such assistance shall be the
           subject of negotiations of a collaborative development project as
           discussed in Section 6.4 below. In

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -19-
<PAGE>

           addition, Amphora may reproduce the software provided with a Product
           for development purposes in accordance with this Article 6, provided
           that such reproduced software shall not be installed on any Product
           unit for which software was not previously purchased from Caliper.

    6.3.   DEVELOPMENT OF MICROFLUIDIC CHIPS AND CHIP CARTRIDGES. Caliper
           reserves all rights to design and otherwise develop the microfluidic
           chip or chip cartridge for use with any Amphora Developed Product. In
           response to any request from Amphora for Caliper to perform such
           activities, Caliper agrees to offer Amphora terms for providing such
           services that are no less favorable to Amphora than those terms
           Caliper generally offers to third parties for similar development. In
           all cases Caliper shall have the right to require that the
           specifications for each microfluidic chip and chip cartridge be
           consistent with then current Caliper design standards and chip
           manufacturing processes.

    6.4.   DEVELOPMENT OF OTHER COMPONENTS. With regard to all components other
           than the microfluidic chip and chip cartridge to be used with any
           Amphora Developed Product, Caliper shall have a right of first
           negotiation as described below to provide any development services
           which Amphora may elect to have provided on its behalf by a third
           party. Before discussing any such project with any third party,
           Amphora shall notify Caliper in writing of the project. Amphora shall
           provide Caliper with relevant, non-confidential information and
           negotiate in good faith with Caliper for at least ten (10) days
           regarding Caliper providing such development services. After such
           period, Amphora shall be free to discuss such project with any third
           party and enter into any development relationship that is consistent
           with this Agreement.

    6.5.   MANUFACTURE AND SUPPLY OF MICROFLUIDIC CHIPS AND CHIP CARTRIDGES.
           Caliper reserves all rights to manufacture and supply each
           microfluidic chip and each chip cartridge for use with any Amphora
           Developed Product, on terms to be negotiated or established in the
           future.

    6.6.   MANUFACTURE AND SUPPLY OF INSTRUMENTS AND OTHER COMPONENTS. With
           regard to instruments and other hardware for use with any Amphora
           Developed Product (not including prototypes or other
           development-stage systems), Caliper shall have a right of first
           refusal as described below to manufacture and supply such hardware to
           Amphora. Caliper shall have no rights of first refusal or
           negotiation, or any other preferential rights, with respect to
           manufacture and supply of software or reagents for use with any
           Amphora Developed Product. Before discussing any manufacturing and
           supply project with any third party, Amphora shall notify Caliper in
           writing of the project. Amphora shall provide Caliper with relevant,
           non-confidential information and negotiate in good faith with Caliper
           for at least ten (10) days regarding Caliper providing such
           manufacturing services. If Amphora and Caliper do not agree during
           such time period, Amphora shall not enter into any such

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -20-
<PAGE>

           agreement with a third party without having previously offered
           Caliper the opportunity to perform such manufacturing on
           substantially similar material terms as the terms offered by such
           third party in a term sheet. Caliper shall accept or reject to any
           such offer by Amphora within ten (10) days. If Caliper accepts the
           offer, then the parties shall make commercially reasonable efforts to
           enter into an agreement within thirty (30) days thereafter. Amphora
           may require that information disclosed to Caliper under this Section
           6.6 shall be treated as Amphora Confidential Information and shall
           not be subject to the license rights granted to Caliper under Article
           7.

    6.7.   NO SALES OF AMPHORA DEVELOPED PRODUCTS. Amphora shall not sell or
           otherwise provide to any third party any Amphora Developed Product,
           except to subcontractors for use on Amphora's behalf pursuant to
           Section 6.8 below or as otherwise set forth in Section 6.1.2.

    6.8.   SUBLICENSING AND THIRD PARTIES. Amphora shall have the right to have
           Amphora Developed Products developed, made or used on its behalf
           pursuant to the license granted in Section 6.1.1 above by any third
           party (a "Subcontractor"), provided Amphora has complied with all the
           other provisions of this Article 6 in doing so, and subject to
           subsections 6.8.1 and 6.8.2.

           6.8.1. INFRINGING SUBCONTRACTORS. Amphora may not engage any third
                 party in any such activities if such third party is otherwise
                 engaged in activities that infringe Caliper Intellectual
                 Property. So that Caliper may monitor this provision, Amphora
                 shall disclose the name of each such third party to Caliper
                 prior to engaging the third party and permit Caliper a
                 reasonable time, not to exceed fifteen (15) days, to
                 investigate and object to such third party on these grounds.

           6.8.2. SUBCONTRACTOR ACKNOWLEDGEMENT. Amphora shall require any third
                 party engaged as a Subcontractor to enter into a written
                 agreement with Amphora expressly agreeing to all of the same
                 restrictions and obligations applicable to Amphora under
                 Section 2.3 of the Intellectual Property Agreement and Sections
                 6.3, 6.5 and 6.7 above. Amphora shall make Caliper a third
                 party beneficiary of such provisions and shall provide Caliper
                 with a copy of such provisions promptly following their
                 execution. Caliper shall have the right to enforce such
                 contractual provisions if Amphora fails to take reasonable
                 actions to address any breach of such provisions within a
                 reasonable time after notice of the breach.

7.  INTELLECTUAL PROPERTY AND RIGHTS TO NEW DEVELOPMENTS

    7.1.   GENERAL RULES ON OWNERSHIP OF INVENTIONS. Except as otherwise
           provided in this Article 7, (i) each party shall solely own all
           inventions, works of authorship, other technology, and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -21-
<PAGE>

           IP, whether patentable or not, created or invented solely by its
           employees and/or consultants and (ii) Caliper and Amphora shall
           jointly own inventions, works of authorship, other technology, and IP
           created or invented jointly by employees and/or consultants of both
           parties, and neither party shall have any obligation to obtain the
           consent of the other party in order to exploit or license such
           inventions, works of authorship, technology, or IP, or any duty to
           account to the other party for profits obtained therefrom. Each party
           shall execute all documents and take all actions reasonably necessary
           to perfect ownership rights of the other party as provided in this
           Article 7 and to enable the filing of patent applications for
           assigned inventions. Inventorship of all inventions covered by this
           Agreement shall be determined under U.S. patent laws.

    7.2.   LABCHIP IMPROVEMENTS.

           7.2.1. PATENTED LABCHIP IMPROVEMENTS. Amphora hereby assigns to
                 Caliper all of Amphora's right, title and interest in and to
                 all Patent Rights to the extent claiming any LabChip
                 Improvements. Caliper shall have the sole right to determine
                 whether to file for any Patent Rights claiming a LabChip
                 Improvement disclosed to Caliper pursuant to Section 7.2.2.
                 below, and to control the prosecution and defense of any Patent
                 Rights with respect thereto. If requested by Caliper, Amphora
                 shall cooperate in patenting activities for such LabChip
                 Improvements, at Caliper's expense, and shall execute any
                 documents necessary to effect such assignment. In exchange for
                 this assignment, Caliper hereby grants to Amphora a
                 royalty-free, non-exclusive, non-transferable (except as
                 provided in Section 14.5), perpetual license under such Patent
                 Rights to use such LabChip Improvements, and have them used by
                 others on Amphora's behalf, in Amphora's Screening Database
                 Business, provided that no rights in any other Caliper
                 Intellectual Property (e.g. background patents) are granted
                 pursuant to this Section 7.2.1.

           7.2.2. UNPATENTED LABCHIP IMPROVEMENTS. For any LabChip Improvement
                 that is not claimed in any patent application or patent,
                 Amphora may elect either to disclose information regarding such
                 LabChip Improvement to Caliper or to retain such information as
                 confidential to Amphora. Caliper may use or disclose freely,
                 without restriction under Article 8 below, any such information
                 that Amphora discloses to Caliper. Such use or disclosure may
                 include, without limitation, inclusion of such information in
                 any patent application filed by Caliper.

           7.2.3. SOFTWARE PATENTS. The parties recognize that Amphora may make
                 software inventions based upon source code provided by Caliper
                 under Section 6.2. Amphora shall grant Caliper a royalty-free
                 non-exclusive license under any Amphora Patent

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -22-
<PAGE>

                 Rights claiming such inventions for use for all applications
                 outside the Screening Database Business.

    7.3.   AMPHORA IMPROVEMENTS

           7.3.1. PATENTED AMPHORA IMPROVEMENTS. Caliper hereby assigns to
                 Amphora all of Caliper's right, title and interest in and to
                 all Patent Rights to the extent claiming any Amphora
                 Improvements. Amphora shall have the sole right to determine
                 whether to file for any Patent Rights claiming an Amphora
                 Improvement disclosed to Amphora pursuant to Section 7.3.2.
                 below, and to control the prosecution and defense of any Patent
                 Rights with respect thereto. If requested by Amphora, Caliper
                 shall cooperate in patenting activities for such Amphora
                 Improvements, at Amphora's expense, and shall execute any
                 documents necessary to effect such assignment. In exchange for
                 this assignment, Amphora hereby grants to Caliper a
                 royalty-free, non-exclusive, non-transferable (except as
                 provided in Section 14.5), perpetual license under any such
                 Patent Rights applicable to Target Assay Protocols to use
                 Target Assay Protocols included in Amphora Improvements, and
                 have them used by others on Caliper's behalf, generally in
                 Caliper's business, but not to sell or otherwise provide such
                 Target Assay Protocols or materially the same Target Assay
                 Protocol to third parties; provided that no rights in any other
                 Amphora IP (e.g. background patents) are granted pursuant to
                 this Section 7.3.1.

           7.3.2. UNPATENTED AMPHORA IMPROVEMENTS. For any Amphora Improvement
                 that is not claimed in any patent application or patent,
                 Caliper may elect either to disclose information regarding such
                 Amphora Improvement to Amphora or to retain such information as
                 confidential to Caliper. Amphora may use or disclose freely,
                 without restriction under Article 8 below, any such information
                 that Amphora discloses to Caliper. Such use or disclosure may
                 include, without limitation, inclusion of such information in
                 any patent application filed by Amphora.

    7.4.   USE OF AMPHORA MATERIALS. Amphora and/or its Affiliates may provide
           to Caliper pursuant to this Agreement certain compounds, substrates,
           reagents and other materials (collectively, the "Materials"), which
           are and shall remain the sole property of Amphora. Any information
           provided in connection with the Materials shall be treated as
           Confidential Information of Amphora, except as otherwise provided in
           this Agreement. The provision of Materials to Caliper under this
           Agreement does not grant Caliper any license or other right to such
           Materials, except the limited right to use the Materials for the sole
           purpose of satisfying its obligations to Amphora under this Agreement
           and for no other purpose, except as otherwise provided in this
           Agreement. Caliper understands that some Materials may have
           unpredictable or unknown biological and/or chemical properties and
           that they should be used with caution. Upon request by Amphora,
           Caliper shall promptly return to Amphora or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -23-
<PAGE>

           destroy any remaining Materials.

    7.5.   NEW LAB-ON-A-CHIP PRODUCTS. The parties recognize that they have
           mutual interests in the development of New Lab-on-a-Chip Products;
           Caliper primarily for purposes of commercializing such products and
           Amphora primarily for purposes of using them in connection with its
           Screening Database Business. Caliper is granting rights under Caliper
           Intellectual Property in Article 6 in order to enable Amphora, not
           just Caliper, to pursue these types of developments. The parties also
           wish to encourage a spirit of open communication and collaboration
           between them in the early investigation of such product
           opportunities, while preserving the freedom in later development
           stages to either collaborate or pursue independent efforts. The
           parties expect that it may be in their mutual interests to pursue
           such opportunities collaboratively. However, they may review and
           discuss such matters on a case by case basis in the future.
           Accordingly, they agree as follows:

           7.5.1. DISCLOSURE AND DEVELOPMENT OF NEW LAB-ON-A-CHIP PRODUCTS. If
                 either party is interested in pursuing development of a New
                 Lab-on-a-Chip Product, it may do so independently or seek a
                 collaborative development agreement with the other party on the
                 terms contemplated in Sections 5.1 and 5.2 or other terms.
                 Either party may choose, in its sole discretion, whether to
                 disclose or not disclose to the other party any or all
                 information concerning an internal project to develop a New
                 Lab-on-a-Chip, and if so, to what extent. Any such information
                 disclosed to the other party, whether in writing, orally or
                 otherwise in the course of the parties' work together
                 ("Disclosed New Lab-on-a-Chip Product Information"), shall be
                 subject to the license granted to the other party in this
                 Section 7.5. However, even if a party elects not to disclose
                 such information with regard to a particular project, such
                 party acknowledges that any Patent Rights arising out of the
                 undisclosed project will nevertheless be included in the
                 following license grant. The parties expressly agree to this
                 provision in order to encourage collaborative efforts and to
                 avoid having either party be "blocked" from developing and
                 exploiting New Lab-on-a-Chip Products by Patent Rights
                 generated by the other party.

           7.5.2. GRANT TO CALIPER. Amphora hereby grants to Caliper a
                 worldwide, fully paid up, royalty-free, non-exclusive,
                 non-transferable (except as provided in this Section and
                 Section 14.5), right and license, under (i) all Patent Rights
                 owned or licensable by Amphora during the Term having an
                 Effective Filing Date between the Effective Date and the
                 expiration or termination of this Agreement, other than Patent
                 Rights acquired by Amphora from third parties, and (ii) all
                 Amphora trade secret and other know-how rights pertaining to
                 Disclosed New Lab-on-a-Chip Product Information, in each case
                 to develop, make, use and sell New Lab-on-a-Chip Products.
                 However, New Lab-on-a-Chip Products developed pursuant to this
                 license shall be subject to the same terms applicable to
                 Screening Products under Article 3 of the Intellectual Property
                 Agreement

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -24-
<PAGE>

                 (Exclusivity for Screening Database Business) except that such
                 terms shall apply for twenty (20) years from the Effective
                 Date, irrespective of expiration or termination of the
                 Intellectual Property Agreement. Caliper may sublicense such
                 rights, subject to the foregoing exclusivity, only to third
                 parties engaged with Caliper in the development, manufacture or
                 sale of New Lab-on-a-Chip Products, and only if (i) such third
                 parties expressly agree to the preceding terms, and (ii)
                 Caliper manufactures and supplies the chip for use in such New
                 Lab-on-a-Chip Product.

           7.5.3. GRANT TO AMPHORA. Caliper hereby grants to Amphora a
                 worldwide, fully paid up, royalty-free, non-exclusive,
                 non-transferable (except as provided in this Section and
                 Section 14.5), right and license, under (i) all Patent Rights
                 owned or licensable by Caliper during the Term having an
                 Effective Filing Date between the Effective Date and the
                 expiration or termination of this Agreement, other than Patent
                 Rights acquired by Caliper from third parties, and (ii) all
                 Caliper trade secret and other know-how rights pertaining to
                 Disclosed New Lab-on-a-Chip Product Information, in each case
                 (a) to develop, make and use New Lab-on-a-Chip Products on the
                 same terms and conditions applicable to Amphora Developed
                 Products under Article 6 of this Agreement and, in addition,
                 (b) with respect to General Assay Protocols and LabChip Assays,
                 and any portion thereof, that have been developed and made
                 pursuant to (a) above and designed to run on instruments and
                 microfluidic chips sold commercially by Caliper or a Caliper
                 Partner, to sell and disclose such LabChip Assays that include
                 Target Assay Protocols developed by Amphora (and tangible
                 embodiments thereof other than microfluidic chips and
                 instruments) to Amphora's Screening Database Business
                 customers. Amphora may sublicense such rights only to third
                 parties engaged with Amphora in the above activities, and only
                 if such third parties expressly agree to the preceding terms.

8.  CONFIDENTIALITY; PUBLICITY

    8.1.   CONFIDENTIAL INFORMATION. During the Term, and for a period of three
           (3) years following the expiration or termination of this Agreement,
           each party shall maintain in confidence any and all Confidential
           Information received from the other party. Each party further agrees
           that it shall not use for any purpose not authorized under this
           Agreement or the Intellectual Property Agreement or disclose to any
           third party the Confidential Information of the other party, except
           that either party may disclose Confidential Information of the other
           party on a need-to-know basis for such purposes to its directors,
           officers, employees, consultants, agents and Affiliates if it shall
           have first required such recipients to undertake an obligation of
           confidentiality and non-use materially as protective as this Section
           8.1. For avoidance of doubt and except as otherwise set forth herein,
           Caliper is authorized to use and disclose the Confidential
           Information of Amphora under this Section 8.1 solely as necessary to
           supply Products to, and perform services for, Amphora under this
           Agreement. Notwithstanding the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -25-
<PAGE>

           provisions of this Section, each party may disclose the other party's
           Confidential Information to the extent such disclosure is reasonably
           necessary to comply with applicable governmental laws, regulations,
           or orders; provided that if a party is required to make any such
           disclosure of the other party's Confidential Information, it will, to
           the extent it may legally do so, give reasonable advance notice to
           such other party of such disclosure and will use its reasonable
           efforts to secure confidential treatment of such information prior to
           its disclosure (whether through protective orders or otherwise).
           Notwithstanding this Section 8.1, the obligations of confidentiality
           and non-use set forth above shall not apply to the extent that the
           provisions of Articles 6 or 7 grant the receiving party rights to
           disclose or use Confidential Information.

    8.2.   PUBLICITY. Neither party shall originate any news release or other
           public announcement (except with regard to SEC or other financial
           reporting obligations) relating to this Agreement without providing
           the other party with the opportunity to review and provide comments
           regarding the contents of such announcement. With regard to SEC or
           other financial reporting obligations relating to this Agreement,
           each party shall make commercially reasonable efforts to consult with
           the other party prior to any public announcements.

    8.3.   CONFIDENTIAL TERMS. The terms of this Agreement shall be Confidential
           Information. Notwithstanding the foregoing, either party may disclose
           this Agreement, under reasonable obligations of confidentiality and
           non-use on a need-to-know basis, to investors and their
           representatives in a private or public financing transaction, to
           potential acquirers or targets and their representatives in a
           corporate change of control transaction, otherwise in connection with
           a merger, acquisition of stock or assets, proposed merger or
           acquisition, or the like, as advisable or required by law (including
           but not limited to the filing of this Agreement as an exhibit to a
           document filed with the Securities and Exchange Commission), order or
           regulation of a governmental agency, to legal counsel of such
           parties, or in connection with the enforcement of this Agreement or
           rights under this Agreement. The disclosing party shall provide
           written notice to the other party of any such disclosure advisable or
           required by law, order or regulation of a governmental agency,
           reasonably in advance if practical. If either party intends to file
           this Agreement with the Securities and Exchange Commission, such
           party agrees to provide the other party with a copy of the proposed
           filing for review and comment at least ten days in advance of the
           filing date. The disclosing party shall not unreasonably withhold its
           acceptance of any comments made by the other party within such
           period.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -26-
<PAGE>

9.  REPRESENTATIONS AND WARRANTIES

    9.1.   GENERAL WARRANTIES. Each Party hereby represents and warrants to the
           other that the statements made in this Section 9.1 are true and
           correct as of the Effective Date:

           9.1.1. AUTHORIZATION; ENFORCEABILITY. The execution and delivery of
                 this Agreement by such Party and the performance of its
                 obligations hereunder and its consummation of the transactions
                 contemplated herein have been duly and validly authorized by
                 all necessary corporate action on the part of such party in
                 accordance with applicable law. This Agreement, when executed
                 and delivered by such party, will constitute a valid and
                 legally binding obligation of such party, enforceable in
                 accordance with its terms.

           9.1.2. NO DEFAULT. The execution and delivery of this Agreement does
                 not, and the consummation of the transactions and performance
                 of the obligations by such party under this Agreement,
                 including the disclosure of any information to the other party,
                 will not: (i) result in any violation of any statute, law,
                 rule, regulation, judgment, order, decree, or ordinance, in
                 each case as in effect as of the Effective Date, applicable to
                 such party, its Affiliates, or an IP owned or licensed to such
                 party or its Affiliates; (ii) conflict with any provision of
                 the bylaws or articles of incorporation of such party or its
                 Affiliates; (iii) result in any breach or default (with or
                 without notice or lapse of time, or both) under any agreement,
                 contract, or other instrument to which such party or its
                 Affiliate is a party; or (iv) result in the creation of any
                 liens, pledges, charges, claims, security interests or other
                 encumbrances of any sort ("Liens") on any IP owned or licensed
                 to such party or its Affiliates.

           9.1.3. CONSENTS. No consent, approval, order or authorization of, or
                 registration, declaration or filing with, any court,
                 administrative agency, commission, regulatory authority or
                 other governmental authority or instrumentality, domestic or
                 foreign (a "Governmental Entity") or any other person or
                 entity, is required by or with respect to such party or its
                 Affiliates in connection with the execution or delivery of this
                 Agreement or the consummation of the transactions or
                 performance of the obligations by Caliper or its Affiliates
                 under this Agreement.

    9.2.   ADDITIONAL WARRANTIES BY CALIPER. Caliper hereby represents and
           warrants to Amphora that the statements made in this Section 9.2 are
           true and correct as of the Effective Date:

           9.2.1. NO NOTICE OF INFRINGEMENT. Caliper has not received notice
                 from any person or entity claiming that the manufacture, use,
                 sale, offer for sale, importation, or other exploitation of any
                 Product infringes or misappropriates the IP of any Person (nor
                 has Caliper determined that there is any reasonable basis
                 therefor), nor has Caliper received

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -27-
<PAGE>

                 notice from any Person claiming that the exploitation of any
                 Product constitutes unfair competition or trade practices under
                 the laws of any jurisdiction. Without limiting the foregoing,
                 no claims with respect to any Product have been communicated to
                 Caliper challenging the ownership or validity of Caliper's
                 rights in or to the Products.

           9.2.2. LITIGATION. There is no action, suit, proceeding, claim or
                 governmental investigation pending or, to Caliper's knowledge,
                 threatened, against Caliper related to any Product.

10. DISCLAIMERS; LIMITATION OF LIABILITY

    10.1.  CALIPER DISCLAIMER. EXCEPT AS SET FORTH IN THIS AGREEMENT, INCLUDING
           THE PURCHASE TERMS OR THE INTELLECTUAL PROPERTY AGREEMENT, THE
           PROVISIONS OF THIS AGREEMENT SHALL NOT BE CONSTRUED AS A PRODUCT
           WARRANTY BY CALIPER OF ANY KIND, EITHER EXPRESS, IMPLIED, STATUTORY,
           OR OTHERWISE, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
           A PARTICULAR PURPOSE, WITH RESPECT TO ANY CALIPER TECHNOLOGY, PRODUCT
           OR OTHER PRODUCTS DEVELOPED OR PROVIDED PURSUANT TO THIS AGREEMENT.
           Caliper shall not be liable to Amphora for any personal injury or
           property damage resulting from use of any Product in a manner that is
           not recommended by Caliper and is not reasonably contemplated or
           intended, except in the case of gross negligence by Caliper, its
           Affiliate or the designee of Caliper or its Affiliate.

    10.2.  AMPHORA DISCLAIMER. AMPHORA MAKES NO REPRESENTATIONS OR WARRANTIES OF
           ANY KIND IN CONNECTION WITH THIS AGREEMENT, AND AMPHORA HEREBY
           EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS, WARRANTIES AND
           CONDITIONS, EITHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE,
           INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
           PURPOSE. Caliper acknowledges that some of the targets and/or
           Materials to be provided to Caliper pursuant to this Agreement are
           for research purposes. Caliper acknowledges that such targets and/or
           Materials can carry risks and must be handled appropriately. Amphora
           shall not be liable to Caliper for any personal injury or property
           damage resulting from the use or handling of such targets and/or
           Materials, except in the case of gross negligence by Amphora or its
           Affiliate.

    10.3.  NO RELIANCE. Neither party has relied upon any representations or
           warranties of the other party in entering into this Agreement except
           as set forth in this Agreement or the Intellectual Property
           Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -28-
<PAGE>

    10.4.  LIMITATION OF LIABILITY. EXCEPT WITH RESPECT TO A BREACH OF SECTION
           8, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY
           INDIRECT OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION, LOST
           PROFITS), EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY
           THEREOF. Each party acknowledges that the foregoing limitations are
           an essential element of the Agreement between the parties and that in
           the absence of such limitations the pricing and other terms set forth
           in this Agreement would be substantially different.

11. INDEMNIFICATION

    11.1.  INDEMNIFICATION. Each party (the "Indemnitor") agrees to indemnify,
           defend and hold harmless each of the other party and its Affiliates,
           and the directors, officers, employees, agents, and contractors, of
           each of such party and its Affiliates, and the successors and assigns
           of any of the foregoing (the "Indemnitees"), from and against any and
           all liabilities, damages, settlements, claims, actions, suits,
           proceedings, penalties, fines, costs and expenses (including, without
           limitation, reasonable attorneys' fees and other expenses of
           litigation) (any of the foregoing, a "Claim") incurred by any
           Indemnitee, based upon a claim of a third party arising from or
           occurring as a result of (i) a breach by the Indemnitor of any
           representation, warranty, or covenant under this Agreement; (ii)
           where Caliper is the Indemnitor, the infringement of a third party's
           IP as a result of the purchase or use of any Product or deliverable
           provided by Caliper or its Affiliate or designee; or (iii) the
           negligence or willful misconduct of the Indemnitor, its Affiliates,
           or its designees that perform services hereunder.

    11.2.  PROCEDURE. If a party intends to claim indemnification under this
           Section 11, it shall promptly notify the Indemnitor in writing of any
           claim, action, or proceeding (each an "Action") in respect of which
           an Indemnitee intends to claim such indemnification, and the
           Indemnitor shall have sole control of the defense and/or settlement
           thereof; provided that the Indemnitee shall have the right to
           participate, at its own expense, with counsel of its own choosing in
           the defense and/or settlement of such Action. The indemnification
           under this Article 11 shall not apply to amounts paid with respect to
           settlement of any Claim if such settlement is effected without the
           consent of the Indemnitee, which consent will not be unreasonably
           withheld or delayed. The failure to deliver written notice to the
           Indemnitor within a reasonable period of time after the commencement
           of any Action, if prejudicial to the Indemnitor's ability to defend
           such Action, shall relieve the Indemnitor of any liability to the
           Indemnitee under this Article 11 with respect to such Action, but the
           omission to so deliver written notice to the Indemnitor shall not
           relieve the Indemnitor of any liability to any Indemnitee otherwise
           than under this Article 11. Without limiting the foregoing, the
           Indemnitee shall keep the Indemnitor reasonably informed of the
           progress of any Action for

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -29-
<PAGE>

           which the Indemnitee intends to claim indemnification under this
           Article 11. The Indemnitor shall not be responsible for any costs or
           expenses incurred by an Indemnitee without the Indemnitor's prior
           written consent, which consent will not be unreasonably withheld or
           delayed.

12. TERM AND TERMINATION

    12.1.  TERM. The term of this Agreement ("Term") shall begin on the
           Effective Date and end at the end of the Exclusivity Period as
           defined in the Intellectual Property Agreement, unless extended or
           earlier terminated pursuant to this Article 12 or modified by mutual
           written agreement of the parties pursuant to Section 14.5.

    12.2.  TERMINATION BY EITHER PARTY. This Agreement may be terminated prior
           to the expiration of the Term only in accordance with one of the
           following paragraphs:

           12.2.1. Either party may terminate this Agreement upon written notice
                 to the other party in the event of a material breach of this
                 Agreement by such other party; provided, however, that prior to
                 any such termination, the terminating party shall have provided
                 the other party with written notice of the circumstances
                 constituting such breach and such other party shall have failed
                 to cure such breach within a period of ninety (90) days
                 thereafter. The foregoing shall not limit a party's right to
                 seek any other remedies available to it, such as monetary
                 damages and specific performance, without termination of this
                 Agreement.

           12.2.2. Either party may terminate this Agreement immediately upon
                 written notice to the other party if the other party is
                 dissolved.

    12.3.  SURVIVING OBLIGATIONS. No expiration or termination of this Agreement
           shall relieve either party of any obligation accruing prior to such
           expiration or termination. With respect to Article 6 and Section 7.5,
           the rights granted therein shall survive, subject to the related
           terms and conditions in such sections, only with respect to Amphora
           Developed Products and New Lab-on-a-Chip Products for which
           development was initiated during the Term. The provisions of Sections
           3.9, 3.10, 4.5.1, 4.5.4, 8.1, 8.3, 10.4, and Articles 11, 12, 13 and
           14, and the reconciliation and reimbursement obligations in Section
           4.5.2 together with any provisions required for their interpretation
           or enforcement, shall survive the expiration or termination of this
           Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -30-
<PAGE>

13. DISPUTE RESOLUTION

    13.1.  ESCALATION. If the parties are unable to resolve any dispute between
           them arising out of or in connection with this Agreement, either
           party may, by written notice to the other, have such dispute referred
           for attempted resolution by good faith negotiations between an
           executive of Caliper and an executive of Amphora (each at the vice
           president level or higher). Such negotiations shall commence within
           thirty (30) days after such notice is received by the other party,
           but neither party shall be obligated to negotiate for more than
           ninety (90) days. If the parties should resolve such dispute or
           claim, a memorandum setting forth their agreement will be prepared
           and signed by both parties if requested by either Party.

    13.2.  ARBITRATION. Caliper and Amphora agree that any dispute arising out
           of or related to this Agreement, or the validity, enforceability,
           construction, performance or breach hereof, which is not settled by
           the parties in accordance with Section 13.1 shall be settled by
           binding arbitration under the then current rules of the American
           Arbitration Association. The venue of such arbitration shall be Santa
           Clara county, CA. The arbitration shall be conducted by a panel of
           three (3) arbitrators appointed in accordance with such rules. Unless
           the decision involves the termination of or otherwise prejudices any
           rights of Amphora arising out of this Agreement, the decision and/or
           award rendered by the arbitrator(s) shall be written, final and
           non-appealable and may be entered in any court of competent
           jurisdiction. The parties agree that, any provision of applicable law
           notwithstanding, they will not request, and the arbitrator shall have
           no authority to award, punitive or exemplary damages against any
           party. The costs of any arbitration proceedings, including
           administrative fees and fees of the arbitrator(s), shall be shared
           equally by the parties. Each party shall bear the cost of its own
           attorneys' and expert fees.

14. MISCELLANEOUS

    14.1   ASSIGNMENT IN BANKRUPTCY. Notwithstanding anything to the contrary,
           each party (the "First Party") hereby consents to the assumption of
           this Agreement by the other party (the "Second Party") in any case
           under chapter 11 of the United States Bankruptcy Code to the extent
           that such consent is required under 11 U.S.C. Section 365(c)(1), but
           only if the Second Party is otherwise entitled to assume this
           Agreement under the requirements of the Bankruptcy Code. The sole
           purpose of the foregoing consent is to overcome any restriction
           imposed by 11 U.S.C. Section 365(c)(1) on the Second Party's
           assumption of this Agreement in a chapter 11 case concerning the
           Second Party. It is not intended to limit any other rights of the
           First Party under this Agreement or any provision of the Bankruptcy
           Code, including, without limitation, 11 U.S.C. Section 365(c)(1). The
           foregoing consent applies only to the assumption of the Agreement by
           the Second Party and does not apply to the Second Party's assignment

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -31-
<PAGE>

           of this Agreement or any rights hereunder to a third party, which
           shall remain subject to all of the terms and conditions of Section
           14.5 of this Agreement.

    14.2   ARTICLE AND SECTION HEADINGS, LANGUAGE AND CONSTRUCTION. The article
           and section headings contained in this Agreement are for reference
           purposes only and shall not affect in any way the meaning or
           interpretation of this Agreement. All references in this Agreement to
           "Articles," "Sections" and "Exhibits" refer to the articles, sections
           and exhibits of this Agreement. The words "hereof," "herein" and
           "hereunder" and other words of similar import refer to this Agreement
           as a whole and not to any subdivision contained in this Agreement.
           The words "include" and "including" when used herein are not
           exclusive and mean "include, without limitation" and "including,
           without limitation," respectively. This Agreement has been negotiated
           by the parties and their respective counsel. Accordingly, this
           Agreement will be interpreted fairly in accordance with its terms and
           without any strict construction in favor of or against either Party.

    14.3   GOVERNING LAW. THIS AGREEMENT, AND ALL DISPUTES ARISING OUT OF OR
           RELATING TO THIS AGREEMENT, SHALL BE GOVERNED BY, AND CONSTRUED AND
           INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF CALIFORNIA,
           WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES OF CALIFORNIA OR ANY
           OTHER JURISDICTION.

    14.4   INDEPENDENT CONTRACTORS. The relationship of Caliper and Amphora
           established by this Agreement is that of independent contractors.
           Nothing in this Agreement shall be construed to create any
           relationship other than independent contractors. Neither Party shall
           have any right, power or authority to assume, create or incur any
           expense, liability or obligation, express or implied, on behalf of
           the other.

    14.5   ASSIGNMENT. Neither Party may assign or otherwise transfer this
           Agreement or any of its rights or licenses hereunder without the
           prior written consent of the other Party hereto, except to a party
           that succeeds to all or substantially all of such Party's business or
           assets, whether by sale of stock or assets, merger, operation of law
           or otherwise; provided that such assignee or transferee agrees in
           writing to be bound by the terms and conditions of this Agreement and
           to continue for one year after the date of the transfer to actively
           pursue the business of, in the case of Amphora, using Screening
           Products for performing Screening Database Business and, in the case
           of Caliper, development, manufacture and sale of microfluidic
           products. Any other attempt by a Party to assign or otherwise
           transfer this Agreement shall be null and void without the prior
           written consent of the other Party. Subject to the foregoing, this
           Agreement will be binding upon and inure to the benefit of the
           Parties and their successors and permitted assigns.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -32-
<PAGE>

    14.6   MODIFICATION. No amendment or modification of any provision of this
           Agreement shall be effective unless in writing signed by both
           parties. No provision of this Agreement shall be varied, contradicted
           or explained by any oral agreement, course of dealing or performance
           or any other matter not set forth in an agreement in writing and
           signed by both parties.

    14.7   SEVERABILITY. If any provision hereof should be held invalid, illegal
           or unenforceable in any jurisdiction, the parties shall negotiate in
           good faith a valid, legal and enforceable substitute provision that
           most nearly reflects the original intent of the parties and all other
           provisions hereof shall remain in full force and effect in such
           jurisdiction and shall be liberally construed in order to carry out
           the intentions of the parties hereto as nearly as may be possible.
           Such invalidity, illegality or unenforceability shall not affect the
           validity, legality or enforceability of such provision in any other
           jurisdiction.

    14.8   FORCE MAJEURE. Neither Party shall be liable to the other for, and
           non-performance shall be excused as a result of, delays or failures
           in performance resulting from causes beyond its reasonable control,
           including earthquakes, fires, riots or civil disturbances, acts of
           war, acts of God, power disruptions, inability to obtain products,
           materials or supplies, acts of government or its agencies, including
           laws, regulations, or judicial action, strikes or other labor
           disputes or disturbances, or communication, utility or transportation
           failures.

    14.9   NOTICES. Any notice or other communication required by this Agreement
           shall be made in writing and given by (i) prepaid, first class,
           certified mail, return receipt requested, (ii) facsimile, or (iii)
           overnight courier; and shall be deemed to have been served on the
           date received by the addressee at such address as may from time to
           time be designated to the other Party in writing:

           If to: Caliper
           Caliper Technologies Corp.
           605 Fairchild Drive
           Mountain View CA 94043-2234
           Attn: Senior Director, Legal Affairs and Corporate Development
           Telefax: 650.623.0500

           If to: Amphora
           Amphora Discovery Corp.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -33-
<PAGE>

           209 Sierra Drive
           Chapel Hill, NC 27514
           Attn: Martin Haslanger
           Telefax: 919.933.6506

    14.10  ENTIRE AGREEMENT. The parties acknowledge that this Agreement, the
           Related Agreements, and the Exhibits of each such agreement, set
           forth the entire agreement and understanding of the parties with
           respect to the subject matter hereof, and supersede all prior and
           contemporaneous discussions, agreements and writings in respect
           hereto, including without limitation the term sheet.

    14.11  COUNTERPARTS. This Agreement may be executed in counterparts, each of
           which shall be deemed an original, but both of which together shall
           constitute one and the same instrument.

        IN WITNESS WHEREOF, the parties have executed the Agreement as of the
date first set forth above.

CALIPER TECHNOLOGIES CORP.                  AMPHORA DISCOVERY CORP.

By: /s/ Daniel Kisner                       By:/s/ Martin Haslanger
    --------------------------------           --------------------------------

Name:Daniel Kisner                          Name:Martin Haslanger
     -------------------------------             ------------------------------

Title: Pres./CEO                            Title:President & CEO
      ------------------------------              -----------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      -34-
<PAGE>

                                    EXHIBIT A
                                 PURCHASE TERMS

1. SOLUTIONS AGREEMENT. These Purchase Terms are hereby incorporated into and
shall be considered a part of this Agreement. All purchases by Amphora of
Products that are listed in Exhibit B of this Agreement ("Existing Products")
shall be subject only to the terms and conditions of this Agreement, including
these Purchase Terms.

2. DELIVERY. Unless otherwise specified in writing by Amphora, shipments shall
be F.O.B. place of shipment. Caliper shall ship all Existing Products prepaid,
properly insured. Title of Existing Products shipped and risk of loss or damage
shall pass from Caliper to Amphora upon Caliper's delivery of Existing Products
to the common carrier specified by Amphora or reasonably chosen by Caliper, if
not specified by Amphora. Caliper shall preserve, package, handle, and pack the
Existing Products so as to protect the Existing Products from loss or damage, in
conformance with good commercial practices, Amphora specifications (if any),
government regulations, and other applicable standards. Caliper shall be
responsible for any loss or damage due to its failure to properly preserve,
package, or handle the Existing Products. Each Existing Product delivered to
Amphora shall include a packing list which contains at least an Amphora Purchase
Order Number, Caliper's part number and description, quantity of Existing
Products shipped, and date of shipment. The purchase price for Existing Products
shall be as set forth in this Agreement. All applicable taxes, freight,
packaging, insurance, handling and other charges will be added to and separately
itemized in the invoice.

3. COMPLIANCE WITH LAW. Amphora will use the Existing Product(s) purchased
hereunder in compliance with all applicable laws and regulations.

4. RETURN MATERIAL AUTHORIZATION. Caliper warrants the Warranty Products (as
defined below) to be free from defects in material and workmanship for the
duration of the Warranty Period (as defined below). If any Warranty Product is
found to have such a defect, Amphora or its designee shall have the right to
return the Warranty Product to Caliper during the following timeframes: for
Warranty Products other than Instrument Systems, at any time during the Warranty
Period, and for Warranty Products that are Instrument Systems, prior to the
earlier of (i) fifteen (15) days after receipt, or (ii) installation. Upon
return of a Warranty Product by Amphora pursuant to the foregoing sentence,
Caliper shall provide a replacement, credit or refund, at Amphora's option,
provided that a refund or credit shall not be available for Instruments Systems.
Subject to the following, any Warranty Product returned to Caliper shall be
accompanied by a Return Material Authorization (RMA). Unless further
verification is reasonably required by Caliper, Caliper shall issue an RMA
within three (3) business days of Amphora's request for return of a noncomplying
Warranty Product. If further verification is so required or if Caliper would
like to attempt to repair the Warranty Product, Caliper may come to Amphora's
facility for such purposes provided that, if desired by Amphora, an RMA shall be
supplied by Caliper to Amphora within ten (10) business days of Amphora's
request for return of the noncomplying Warranty Product if Caliper has failed to
repair

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

the Warranty Product or establish that the Warranty Product is not defective, by
such time. If Caliper fails to provide the RMA, and the Warranty Product has not
been repaired within the foregoing timeframes, Amphora shall have the right to
return the Warranty Product without an RMA. Amphora shall additionally have the
right, at its sole option and Caliper's sole cost, to require Caliper to repair
the nonconforming Warranty Product pursuant to the terms of Section 6 below.
Caliper shall bear the freight and insurance charges of any Warranty Product
returned by Amphora under this Section, if properly rejected by Amphora.

5. CHIP AND INSTRUMENT WARRANTIES. Caliper warrants that, (i) with respect to
Existing Products that are Instrument Systems, for a period until the earlier of
one year from the completion of installation testing or fifteen (15) months from
the date of delivery in good condition to Amphora in accordance with this
Agreement, and (ii) with respect to Existing Products that are Chips, for a
period until three (3) months from the date of delivery in good condition of a
Chip to Amphora in accordance with this Agreement (each, a "Warranty Period"),
the Existing Products that are Instrument System(s) or Chips (each, a "Warranty
Product") purchased by Amphora hereunder will be free from defects in material
and workmanship, and will perform in accordance with Specifications. If the
Warranty Product fails to comply with the warranty in this Section 5 during the
Warranty Period and the Warranty Product has not been returned pursuant to
Section 4, Caliper will (i) for Warranty Products that are Instrument Systems,
repair or replace them, at Caliper's option and at Caliper's expense, within the
time frames set forth in Section 6 below, and (ii) for Warranty Products that
are Chips, Caliper will replace them upon completion of its review of the
warranty claim as contemplated in Section 4.2.2.3 of this Agreement, but in no
event later than thirty (30) days after the claim has been submitted by Amphora,
provided that Caliper shall make commercially reasonable efforts to replace
defective Chips prior to the end of such thirty (30) day period. If the Warranty
Product has been returned pursuant to Section 4, the remedy shall be as set
forth therein. If the Warranty Product becomes damaged, or the performance of
the Warranty Product otherwise deteriorates due to solvents and/or reagents
other than those supplied or expressly recommended by Caliper or otherwise
materially similar to those supplied or expressly recommended by Caliper,
Caliper will repair or replace the Warranty Product, at Amphora's option and at
Amphora's expense. No such repairs or replacement will extend the original
Warranty Period. This Warranty does not apply to any Warranty Product or part
which has been (a) the subject of an accident, misuse, or neglect after shipment
to Amphora in accordance with this Agreement, (b) modified or improperly
repaired by a party other than Caliper or its authorized representative, or (c)
used in a manner which is not in accordance with the instructions contained in
the Warranty Product User's Manual; provided that such use is not a reasonably
contemplated use of the Warranty Product. This warranty does not cover
Amphora-installed accessories or Amphora-installed consumable parts for the
Warranty Product that are listed in the Warranty Product User's manual; provided
that such accessories and consumables are not themselves Warranty Products. All
claims under Caliper's warranty must be made within thirty (30) days of
Amphora's discovery of the defect. Except for Caliper's right to obtain a credit
or refund as provided under Section 4, Caliper's obligations under this warranty
are limited to repair or replacement as necessary to

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

correct those defects in material and/or workmanship or failures of the Warranty
Product to meet the Specifications of which Caliper is notified within thirty
(30) days after the expiration of the Warranty Period. All repairs and
replacements performed by Caliper under this warranty will be performed by
Caliper at Caliper's sole expense, it being acknowledged that proper repairs and
maintenance by Amphora will not void the warranty. Except pursuant to written
terms signed by an officer of Caliper, no agent, employee, or representative of
Caliper has any authority to bind Caliper to any affirmation, representation, or
warranty concerning the Warranty Product that is not contained in Caliper's
printed product literature or the Specifications. Any such affirmation,
representation, or warranty made by any agent, employee, or representative of
Caliper not pursuant to written terms signed by an officer of Caliper will not
be binding on Caliper. Caliper makes no warranty whatsoever with regard to
products or parts furnished by third parties, unless such product or part is
provided by Caliper as part of a Warranty Product. This warranty is limited to
the original location of installation and is not transferable, except that (a)
this warranty shall apply in Mountain View and North Carolina to the initial
Instrument Systems purchase that will be first installed in Mountain View and
then transferred to North Carolina and (b) this warranty shall apply
notwithstanding any transfer made by Caliper or by Amphora's representatives
that have been certified as having received the appropriate training from
Caliper, which training and certification Caliper shall make reasonably
available to Amphora pursuant to the terms of Article 3 of this Agreement. This
warranty is the sole and exclusive warranty as to the Instrument System and is
in lieu of any other express or implied warranties, including, without
limitation, any implied warranty of merchantability or fitness for a particular
purpose and is in lieu of any other obligation on the part of Caliper. THIS
PARAGRAPH STATES AMPHORA'S SOLE AND EXCLUSIVE REMEDY FOR BREACH OF WARRANTY. IN
NO EVENT SHALL CALIPER BE LIABLE FOR ANY USE, OR INABILITY TO USE, BY AMPHORA OF
THE PRODUCT(S) EXCEPT THAT CALIPER SHALL BE OBLIGATED TO PERFORM ITS
RESPONSIBILITIES SET FORTH IN THESE PURCHASE TERMS; NOR SHALL CALIPER BE LIABLE
FOR ANY PUNITIVE, CONSEQUENTIAL, INCIDENTAL, INDIRECT OR SPECIAL DAMAGES ARISING
FROM OR IN CONNECTION WITH ITS ACTIVITIES UNDER THESE PURCHASE TERMS, INCLUDING
WITHOUT LIMITATION ANY PUNITIVE, CONSEQUENTIAL, INCIDENTAL, INDIRECT OR SPECIAL
DAMAGES FOR LATE DELIVERY OF THE PRODUCT(S), EXCEPT AS OTHERWISE SET FORTH IN
THE SOLUTIONS AGREEMENT.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

6. INSTRUMENT REPAIR AND MAINTENANCE. Caliper shall respond to Amphora's initial
call for service for an Instrument System with a telephone call to Amphora by a
qualified Caliper technical service representative within four (4) of Caliper's
normal business hours after Amphora's call. Caliper shall have a qualified
Caliper technical service representative at Amphora's site, if Amphora is
experiencing a warranty or maintenance issue with an Instrument System, within
seventy-two (72) hours of Amphora's request for warranty or maintenance services
on an Instrument System, subject to any force majeure event as set forth in this
Agreement. Upon arrival, the service representative shall work diligently toward
resolution of the warranty or maintenance issue. Caliper shall make commercially
reasonable efforts to repair an Instrument System within five (5) business days
of Amphora's request for warranty or maintenance services, it being acknowledged
that what constitutes reasonable efforts will take into account any force
majeure event or extraordinary damage. If not corrected within such time period,
Caliper will continue to use commercially reasonable efforts to correct the
problem as soon as reasonably practicable. If the Existing Product is under
warranty, Caliper shall install a replacement product within forty-five (45)
days after Amphora's request for warranty services if the defect has not been
remedied by such time. The foregoing warranty repairs shall be at no charge to
Amphora during the Warranty Period. Caliper shall provide to Amphora any
additional support services for the applicable Existing Products that Caliper
provides generally to its customers upon the terms generally provided to its
customers. The Warranty Period for any Warranty Product replaced under this
warranty shall begin upon the installation or delivery in good condition of the
replaced Warranty Product, as provided in Section 5.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                    EXHIBIT B
                           CALIPER SCREENING PRODUCTS

HTS 250 PRODUCT CATALOG:

     PRODUCT                                 SYSTEM

     CALIPER 250 CORE SYSTEM
                                             MOBILITY SHIFT AND FLUOROGENIC
     -2-CCD Detection                        SCREENING SYSTEM
     -Blue and Red excitation lasers         -Caliper 250 Core System
     -16V+1P Power and Pressure Controller   -Option 1*: Environmental
                                             Control and Multi-Plate Handling
     -Computer System                        -Option 2*: Addition of UV
                                              Excitation and Detection
     -X-Y-Z robot system w/controller        -Fluorogenic Analysis Module
     -Next Gen Instrument Control and Data   -Off-Chip Mobility Shift Analysis
     Acquisition Software                    Module
     -Includes 3 Training Credits

     OPTION 2*: ADDITION OF UV
     EXCITATION AND DETECTION                MOBILITY SHIFT SCREENING SYSTEM
     -355nM Excitation and Detection         -Caliper 250 Core System
                                             -Option 1*: Environmental Control
                                             and Multi-Plate Handling
                                             -Off-Chip Mobility Shift Analysis
                                             Module
     ANALYSIS SOFTWARE

     -4-Sipper Fluorogenic Chip              MOBILITY SHIFT AND FLUOROGENIC
     -Fluorogenic Price/Datapoint            DEVELOPMENT SYSTEM
                                             -Caliper 250 Core System
                                             -Option 2*: Addition of UV
                                             Excitation and Detection
                                             -Fluorogenic Analysis Module
                                             -Off-Chip Mobility Shift Analysis
                                             Module

                                             MOBILITY SHIFT DEVELOPMENT SYSTEM
                                             -Caliper 250 Core System
                                             -Off-Chip Mobility Shift Analysis
                                             Module

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                    EXHIBIT C
                               INSTRUMENT PRICING

TABLE A
-------

<TABLE>
<CAPTION>
# OF INSTRUMENT SYSTEMS*                       DISCOUNT OFF [ * ]
---------------------------------------------- -------------------------------------------
<S>                                            <C>
[ * ]                                          [ * ]
---------------------------------------------- -------------------------------------------
[ * ]                                          [ * ]
---------------------------------------------- -------------------------------------------
[ * ]                                          [ * ]
---------------------------------------------- -------------------------------------------
[ * ]                                          [ * ]
---------------------------------------------- -------------------------------------------
[ * ]                                          [ * ]
---------------------------------------------- -------------------------------------------
</TABLE>

BY WAY OF EXAMPLE, THE FIRST CLASS I INSTRUMENT SYSTEM PURCHASED BY AMPHORA
DURING THE FIRST CONTRACT YEAR [ * ]. THE [ * ] CLASS I INSTRUMENT SYSTEM
PURCHASED BY AMPHORA IN THE SAME CONTRACT YEAR SHALL BE PRICED AT A [ * ]. THE
DISCOUNT RATE FOR CLASS II INSTRUMENT SYSTEMS SHALL BE DETERMINED IN THE SAME
MANNER AS THE FOREGOING. THE RATE SCHEDULE SHALL RESET TO [ * ] DISCOUNT FOR
EACH CLASS AT THE BEGINNING OF THE SECOND CONTRACT YEAR.

TABLE B
-------

CURRENT INSTRUMENT SYSTEMS
----------------------------------------------------------------
CLASS I
----------------------------------------------------------------
  -- CALIPER 250 MOBILITY SHIFT AND FLUOROGENIC SCREENING
SYSTEM
----------------------------------------------------------------
  -- CALIPER 250 MOBILITY SHIFT SCREENING SYSTEM
----------------------------------------------------------------
CLASS II
----------------------------------------------------------------
  -- CALIPER 250 MOBILITY SHIFT AND FLUOROGENIC DEVELOPMENT
SYSTEM
----------------------------------------------------------------
  -- CALIPER 250 MOBILITY SHIFT DEVELOPMENT SYSTEM
----------------------------------------------------------------

* THE AGGREGATE NUMBER OF CURRENT AND FUTURE INSTRUMENT SYSTEMS ORDERED WITHIN
EACH CLASS OF INSTRUMENT SYSTEMS AND WITHIN THE FIRST OR SECOND CONTRACT YEAR

** [ * ].

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]